

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

Proactive Research and Development activities. (अन्वेषणम्)

- **Sensitization amongst faculty members and students for research**
- **Research MoU's and Collaborations**
- **Facility Creation for Research (Installation reports examples)**
- **Intensified Collaborative Research Activities (Joint Patents and**
- **Publications examples)**
- **Notable achievements for Research and Innovations**

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

Sensitization amongst faculty members and students for research

1. Research Policy

**Dr. D. Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune - 411018.**

RESEARCH POLICY

AIMS OF THE POLICY

- Provide the guidelines for the conduct of research work.
- To promote and facilitate quality research activities amongst the faculty and students.
- To foster an environment conducive for research.
- To encourage faculty and students to participate in research projects to improve their technical skills and knowledge.
- Provide essential infrastructure support for the research work.
- To assist faculty in obtaining research grants from various funding bodies.

GENERAL GUIDELINES IN PUBLISHING THE RESEARCH OUTPUTS

1. Authorship criteria should be strictly followed.
A person can be included as an author if he/she fulfils ALL of the following:
 - Contribution in conceiving and design of the study.
 - Contribution in acquisition, analysis or interpretation of data.
 - Contribution in the critical evaluation of intellectual content.
 - Take consent of all the authors for the publication.
 - The order of authors must be directly proportional to the contribution made towards the research work.
 - Due credit should be given to the Institute in the publication in the acknowledgment section.
2. Faculty should cite publications of fellow faculties in their respective publications
(Considering the research domain)
3. All faculties should provide data of their R&D activities in format prescribed by R&D committee monthly by email as well as hard copies to be submitted at the same time.
4. Biannual review of all R and D related activities will be carried.

PRECAUTIONS TO BE TAKEN WHILE SELECTING A JOURNAL FOR PUBLICATION:

- All publications should be in journals indexed in Scopus and/or Web of Science.
- Beware of predatory journals.
- Authors may decide the journal depending upon quality of the research work.
- All contribution made should be free from plagiarism.

MINIMUM CRITERIA FOR R & D ACTIVITIES

- **For Assistant Professor / PhD scholar/Research co-guide (Below 5 years experience)**
 - ✓ Min. 01 presentation/year
 - ✓ Min. 01 Seminar/workshop attended/year
 - ✓ Min. 01 research/ review publication
 - ✓ Min. 01 FDP and 01 NPTEL/ Swayam/ Coursera etc. Certificate course
- **For Assistant Professor / PhD scholar/Research co-guide (Above 5 years experience)**
 - ✓ Min. 01 presentation/year
 - ✓ Min. 01 Seminar/workshop attended/year
 - ✓ Min. 02 research/ review publication or equivalent to number of PG and PhD students guided(Whichever is higher)
 - ✓ Min. 01 research project submitted to any funding body.
 - ✓ Min. 01 FDP and 01 NPTEL/ Swayam/ Coursera etc. Certificate course
- **For Associate Professor/Professor**
 - ✓ Min. 01 Seminars/workshops attended/year
 - ✓ Min. 02 research/ review publications or equivalent to number of PG and PhD students guided(Whichever is higher)
 - ✓ Min. 02 research project submitted to any funding body.
 - ✓ Min. 01 Invited session
 - ✓ Min. 01 FDP and 01 NPTEL/ Swayam/ Coursera etc. Certificate course

Note:

- Year is considered as academic year.
- In case of research publications, calendar year will be considered.

- Only participation in External Seminars/ Workshops/ Presentations (Outside the institute) will be considered.
- All faculties should furnish data of participation of their respective research students in any R and D related activities.
- All faculties should take efforts to satisfy the minimum criteria set for R and D contribution.
- Activities beyond the minimum criteria are encouraged.

RESEARCH INCENTIVES

Research has always been an integral part of our development.


In order to strengthen the research activities, we propose to have certain incentives for faculty and PG students as under:

Sr.No	Research component	Criteria for Award	Research Incentive
1.	Research publication (For Faculty)	Min Criteria • Publication in Scopus/Web of science indexed journal • Recognized Publishing house(Elsevier, Pubmed, Taylor and Francis, ACS, Springer, Wiley etc) • Only First Author or Corresponding author in case the author is guiding a PhD scholar who is not a faculty at the institute.	
1a		Impact factor bet 1.00-2.00	1000/publication
1b		Impact factor bet 2.00-5.00	2000/publication
1c		Impact factor above 5.00	5000/publication
2.	Funded Research projects/ Industry sponsored Research projects/	• Only one incentive can be claimed under each project. • In case PI and Co-PI are involved, the incentive will shared.	

2a	Consultancy activities (For Faculty)	Funding between 1.00 lac - 4.00 lacs	1% of the total grant received
2b		Funding between 4.00 lac - 10.00 lacs	2% of the total grant received
2c		Funding above 10.00 lacs	3% of the total grant received
3	Patents	• Patent that is published in the Indian Patent Journal/World Intellectual Property Organization/other reputed international patent databases. • Only one incentive can be claimed per patent	5000/patent
4	Attending Seminars/Conferences/Skill based training (For Faculty and Students)	Registration fees will be reimbursed on submission of receipt by a faculty member for contributions in the way of: (a) Presentation of Paper / Poster (b) Chairing a session (c) Judging a scientific paper / poster session (d) Delivering a guest lecture	Registration fee as stated in the brochure of the Seminar/Conference

This research policy will be effective from 1st January 2020 and will be reviewed after every 5 years or as required from time to time.


Dr. A. B. Thomas
R & D Co-ordinator


Dr. S.S. Chitlange
Principal

Dr. D. Y. Patil Vidya Pratishthan Society's
Dr. D. Y. Patil Institute of Pharmaceutical Science & Research,
Pimpri, Pune-18.

Approval No:-2016/267

Date: 16/05/2016

To,
Hon. Chairman
Dr.D.Y.Patil Vidya Pratishthan Society
Pimpri, Pune-18

Subject: Financial approval for deputing faculty for State level/ National level seminar/ conferences/ workshops

Respected sir,

With reference to above subject, as desired by all accrediting agencies and as a matter of quality policy, we should depute all our regular teaching faculty(Parmanant and Adhoc) for attending National/ State level seminars/ conferences/ workshop. This will boost the research culture of the institute and faculty will get exposure to the current trends in their research domain.

In this regard, every faculty member should be paid Rs. 10,000/- towards registration charges and TA/DA for attending National/ State level seminars/ conferences/ workshop during every academic year.

I am to request you to kindly approve this amount for every faculty member on yearly basis from academic year 2016-17 onwards on oblige.


Thanking you


(Mr. V.D. Takawane)
Registrar

Your's truly

Approved/ Not Approved


(Dr. P. D. Patil)
Chairman


(Dr.S.S.Chitlange)
Principal

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

Research MoU's and Collaborations

- 1. National Chiyayi University, Taiwan**
- 2. E.A. Buketov Karaganda University, Kazakhstan**
- 3. Ivan Franko National University, Ukraine**

**MEMORANDUM OF UNDERSTANDING
BETWEEN**

**College of Life Sciences, National Chiayi
University, Taiwan**

AND

DPU

***Dr. D. Y. Patil Unitech Society's,
Dr. D. Y. Patil Institute Pharmaceutical
Sciences & Research, Pimpri, Pune.***



MEMORANDUM OF UNDERSTANDING

between

COLLEGE OF LIFE SCIENCES, NATIONAL CHIAYI UNIVERSITY, TAIWAN

and

**DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH,
PIMPRI, PUNE-INDIA**

In accordance with a mutual desire to promote academic cooperation between NATIONAL CHIAYI UNIVERSITY, TAIWAN (hereinafter "NCYU") and DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PIMPRI, PUNE-INDIA (hereinafter "DPU Pharmacy") the undersigned parties agree to cooperate under the terms of the following agreement.

RECITALS

WHEREAS, NCYU and DPU Pharmacy both have health science-related programs and affiliated health care systems that are involved in biomedical/pharmaceutical/natural product research and the related education of students;

NOW THEREFORE, in contemplation of the mutually beneficial relationships to be established, and in consideration of the mutual promises and covenants contained herein, the sufficiency of which is hereby agreed to and accepted, the Parties agree as follows:

TERMS

Purpose of the MOU: Definition.

- a. The primary objective of this MOU is to create a means for cooperative efforts between NCYU and DPU Pharmacy to affect the academic and research interchange of faculty and students, and academic and research information between the two Institutions.
- b. "Home Institution" refers to the Institution sending its student(s), or faculty member(s) to the other Institution for the purposes of study, learning, teaching and/or research.
- c. "Receiving Institution" refers to the Institution hosting the visiting student(s), or faculty member(s) from the other Institution for the purposes of study, learning, teaching, and/or research.

ARTICLE 1:

NATIONAL CHIAYI UNIVERSITY, TAIWAN and DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PIMPRI, PUNE-INDIA, agree to promote the following activities to enhance each other's educational, academic, and research activities:

1. Exchange of faculty members and researchers:

- a) NCYU and DPU Pharmacy will actively seek to promote mutual faculty exchange for mutual agreed periods.
- b) Faculty exchange may assume various forms, such as individual short-time and long term visits of faculties, joint research and development projects.
- c) NCYU and DPU Pharmacy will try to seek external funding sources to facilitate these exchanges.



- d) Encouragement of the academic faculty to co-author publications, joint research activities and joint project possibilities is in subject to applicable copyright and / or other laws of each country, as well as rules and regulations of the perspective Institution.
- e) The host institution will endeavor to, as much as possible, make available such facilities that will enable the faculty to obtain experience and training in its departments and institutes, including the use of its laboratories and libraries.
- f) NCYU and DPU Pharmacy acknowledge that in the absence of an external funding agency, all expenses for travel, living and allied costs will be left to the discretion and the responsibility of the home Institution.
- g) Any Intellectual Property developed during the joint activity will be jointly owned by the two Institutions.

2. Student exchange programs in terms of short-term visit and internship:

- a) The aim of the exchange program is to provide students an opportunity to have experience of international cooperation and exchange, as well as to gain a better understanding of Taiwan and India through education.
- b) The term of study for exchange students participating in this program will be mutually decided by two parties.
- c) NCYU and DPU Pharmacy also agree to accommodate the students in the academic programs available in both the institution (PG/ PhD) in condition to meet all applicable regulatory and admission standards of the Receiving Institution and obtain all required approvals from the Home Institution for participation in a Program. These standards include but are not limited to requirements for language proficiency; medical training and experience; license (if required); professional liability insurance as applicable; personal health and travel insurance; vaccinations; VISA applications and other necessary governmental approvals or permissions.
- d) The host university shall reserve or make available accommodation on campus or assist them to make alternative arrangement.
- e) Any Intellectual Property developed during the joint activity will be jointly owned by the two Parties.

3. Exchange of information and academic resources that are of mutual interests:

- a) NCYU and DPU Pharmacy will exchange information on research and educational



programmes and teaching/learning material and other literature relevant to their educational and research programmes. Further NCYU and DPU Pharmacy agree to explore ways to share teaching/learning material, and other relevant literature, while respecting each other's intellectual property and other rights.

4. Activities such as collaborative research, joint symposia, and exchange lectures

- a) NCYU and DPU pharmacy both are agreed to undertake joint collaborative research, joint symposia on the area of mutual interest. The cost of such research projects will be shared amongst both the institution. Both the parties also agreed to submit the joint research/symposia proposal/s to the funding agencies (if any).
- b) NCYU and DPU Pharmacy also, agreed to help identify and invite faculty members from the other institution to participate in conferences, workshops and short-term courses. The terms and conditions for such participation will be worked out by mutual agreement between NCYU and DPU Pharmacy.
- c) All publications resulting from the educational, research, or any other collaboration between the two Institutions shall acknowledge the existence of the collaboration formed under this MOU. Likewise, the relationship between the Parties shall be mentioned in all courses and formal presentations which result from any collaboration formed under this MOU.
- d) Each research project conducted jointly by the Parties shall be made under a formal written research collaboration agreement containing whatever terms the Parties mutually agree are necessary to address the intellectual property, research information and property interests that could result from the joint activity of the Parties. All such discussions of the Parties regarding these matters will at all times strive to preserve a harmonious and continuing relationship between the Parties.
- e) All research and other activities conducted under this MOU must be conducted in accordance with the laws, rules, and regulations applicable to each Institution. In the case of NCYU, these are the laws, rules, and regulations of the Govt. of Taiwan. In the case of DPU Pharmacy, these are the laws, rules, and regulations of Govt. of India.

5. Development of collaborative academic programs

- a) Both the parties are agreed for the development of the collaborative academic program mutually fit as per the requirement. NCYU and DPU pharmacy will be responsible to take the necessary approvals (if any) for such programs. The development of such program



will be abide as per the education law and policies in existence in both countries.

ARTICLE 2:

Matters pertaining to the implementation of the exchange based on this agreement shall be negotiated and agreed upon by representatives of the two parties.

ARTICLE 3:

None of the parties shall use the name, logo, likeness, trademarks, image or other intellectual property of either of the other parties for any advertising, marketing, endorsement or any other purposes without the specific prior written consent of an authorized representative of the other party as to each such use.

ARTICLE 4:

This agreement shall become effective on the date of which it has been signed by both parties, and it shall be in force for five years. Revision and modification of the agreement may be implemented by mutual agreement of both signatories subject to a six-month minimum notification period prior to the expiration of the existing agreement. Either party may terminate this agreement at any time with a six-month notice in advance.

The renewal of this agreement shall be discussed by both parties no less than six months prior to the expiration of this agreement.

ARTICLE 5:

This agreement is to be executed by joint signature of two identical copies, written in English with each party retaining one copy.


(Dr. Ruoy-Shyang Chen)

Dean
College of Life Sciences
National Chiayi University
TAIWAN
Date 12/23/2020


(Dr. S. S. Chitlange)

Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 23/12/2020



Memorandum of Understanding

Between



E.A. Buketov Karaganda University, Kazakhstan

And



**Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune, India**

**Ғылым және білім беру қызметтерін көрсету
саласында өзара ынтымақтастық туралы
КЕЛІСІМ-ШАРТ**

Қарағанды қ.

« 16 » 04 2024

«Академик Е.А. Бөкетов атындағы Қарағанды университеті» КеАҚ (Қазақстан Республикасы), Басқарма төрағасы – ректор, профессор Дулатбеков Нұрлан Орынбасарұлы, бірінші тараптан және д-р Д. Ы. Патил, фармацевтикалық ғылымдар институты, Пимпри қ., Пуна ауданы (Индия), директор (институт басшысы) атынан д-р Сохан С. Читланджи мен доцент д-р Бhole Р. П., екінші тараптан бұдан әрі – «Келісуші тараптар», білім және ғылым саласындағы өзара тиімді ынтымақтастықты жалғастыру мақсатында келесі келісім шарт жасасты.

1. Келісім-шарт мәні

1.1 Осы Шарттың мәні – университет өмірінің әр түрлі салаларында тең құқылық пен өзара тиімділік негізінде даму.

2. Келісуші Тараптардың міндеттері

2.1. Келісуші тараптар ынтымақтастық шеңберінде келесі міндеттемелерді қабылдайды:

- өзара келісілген тақырыптар бойынша бірлескен ғылыми зерттеулерді ұйымдастыру, ғалымдармен, оның ішінде Хирш индексі жоғары ғалымдармен алмасу және бірлескен ғылыми еңбектер шығару, кафедралар, зертханалар және басқа ғылыми бөлімдер арасындағы байланысты дамыту және қолдау;
- ақпаратпен, басылымдармен және басқа да ғылыми және ғылыми-әдістемелік материалдармен үнемі алмасуға, әр университетте өткізілетін ғылыми іс-шаралар туралы бір-біріне хабарлауға және басқа тарап өкілдерін осы іс-шараларға қатысуға шақыруға;
- студенттермен, ғылыми қызметкерлермен және академиялық құраммен алмасуды жүзеге асырады, оларға теориялық және практикалық білімді кеңейту үшін барлық жағдайларды жасайды, сондай-ақ белгіленген тәртіппен жатақханаларға орналастырады;
- бірлескен білім беру бағдарламаларын дамыту;
- тараптардың біреуі өткізетін ғылыми конференцияларға, семинарларға өзара негізде қатысуға және ғылыми зерттеулердің нәтижелерін Тараптардың мерзімді және ғылыми басылымдарында ұсынуға;
- бірлескен білім беру және мәдени бағдарламалар, семинарлар, тренингтер, конкурстар мен конференциялар өткізуге;
- магистратура және докторантура бағдарламалары бойынша студенттердің оқу жетістіктерімен транскрипт (сертификат) бере отырып, магистратура мен докторантура бойынша толық немесе ішінара оқу мүмкіндігін қамтамасыз

**CONTRACT
on Mutual Cooperation in the Provision of
Educational and Scientific Services**

c. Karagandy

« 16 » 04 2024

NLC “Karagandy University of the name of academician E. A. Buketov” (the Republic of Kazakhstan) on behalf of the Chairman of the Board – Rector, Professor Dulatbekov Nurlan Orynbasarovich, from the one side, and Dr. D. Y. Patil Institute of Pharmaceutical Sciences, Pimpri, Pune (India), on behalf of Principal (Head of the Institute) Dr. Sohan S. Chitlange and Dr. R. P. Bhole Associate Professor, from the other side, hereinafter mentioned as “Agreeing parties”, concluded following agreement with the aim of mutually beneficial cooperation continuation in education and science sphere.

1. Object of Agreement

1.1 Object of Agreement is development on the basis of equal rights possession and mutually profitable cooperation in different spheres of university life.

2. Obligations of Agreeing Parties

2.1. Agreeing parties in frames of cooperation accept following obligations:

- to cooperate in the field of scientific work through the organization of joint scientific research on mutually agreed topics, the exchange of scientists, including those with a high Hirsch index, and the publication of joint scientific works, developing and maintaining contacts between departments, laboratories and other scientific departments;
- to exchange regularly with information, publications and other scientific and scientific-methodical materials, to inform each other about scientific activities being held at each university, and to invite representatives of other side to take part in this activities;
- to perform the exchange of students, scientific workers and academic staff, rendering them all necessary conditions for enlarging theoretical and practical knowledge, and also provide with placements in dormitories in established order;
- to develop joint educational programs;
- to take part on mutually bases in scientific conferences, seminars, that are held by one of the sides, and to represent results of scientific research in periodical and scientific publications of Sides;
- to carry out joint educational and cultural programs, seminars, trainings, contests and conferences;
- to provide opportunity of full or partial (during one academic period) study on master and doctorate training programs with issuance of transcript (certificate) with academic achievements of student and rendering the opportunity of defense of results of scientific research and gaining of academic degrees on specialties offered at appropriate institution;
- to provide with assistance in vocational training of academic teaching staff through courses of vocational

ету және ғылыми зерттеу нәтижелерін қорғау және тиісті оқу орнында ұсынылатын мамандықтар бойынша ғылыми дәрежелер алу мүмкіндігі;

– тиісті оқу орнында ұсынылатын мамандықтар бойынша докторантура, пост-докторантура және магистрді кәсіби даярлау курстары арқылы академиялық педагогикалық кадрларды кәсіптік даярлауға көмек көрсету;

– оқытушыларға, қызметкерлерге және студенттерге тиісті мекемеде ұсынылатын мамандықтар бойынша ғылыми және/немесе кәсіби практика (тағылымдама) мүмкіндігін беру;

– студенттер мен оқытушылар құрамының ғылыми-әдістемелік жұмыстарына өзара шолу жасау;

– ұлттық заңнамаларға сәйкес ғалымдардың Тараптардың диссертациялық кеңестерінің жұмысына қатысуын жеңілдету;

– Тараптардың студенттері, оқытушылары мен қызметкерлерінің жақын және алыс шет елдердің университеттерімен және ғылыми орталықтарымен академиялық ұтқырлығын дамытуға көмек көрсету, басқа Тараптың халықаралық ынтымақтастығын кеңейтуге ықпал ету;

– монографияларды, ғылыми зерттеулерді, ғылыми жинақтарды басып шығару жоспарлары жайлы бір-біріне хабарлауға;

– білім берудің прогрессивті әдістерін дамыту және кредиттік аудару жүйесін енгізу бойынша тәжірибе алмасу;

2.2. Университет саясаты мен әкімшілігі саласында келіссөз жүргізуші тараптардың өзара іс-қимылы тәжірибе алмасу және жоғары оқу орындары арасындағы ынтымақтастықтың нәтижелерін шығару үшін осы қызмет саласындағы қызметкерлердің алмасуымен ұйымдастырылуы мүмкін екендігі жоқ емес.

3. Өзге жағдайлар

3.1. Осы Келісім тараптардың біреуінің бастамасы бойынша талқылауға ұсынылу мүмкіндігі бар ынтымақтастықтың басқа түрлерін жоққа шығармайды, сондай-ақ жазбаша түрде толтырылуы және өзгертілуі және өкілдердің қол қоюы мүмкін.

3.2. Осы Келісімнің мәлімдемелерін жүзеге асыру үшін келісуші тараптар нақты жұмыс формаларын, ғылыми тақырыптарын, ынтымақтастық шарттары мен квоталарын, сондай-ақ оны ұйымдастырудың және қаржыландырудың тәртібі мен шарты болуы мүмкін ынтымақтастықтың жаңа жұмыс бағдарламаларын әзірлеп, мақұлдай алады.

4. Қорытынды мәлімдемелер

4.1. Осы Келісім-шарт Тараптармен қол қойылған кезден бастап күшіне енеді және 5 (бес) жыл бойы дәл 2026 жылдың _____ наурызына дейін әрекет етеді.

4.2. Тараптар басқа Тарапты мүдделері туралы

training of doctorate, post-doctorate and master on specialties offered at appropriate institution;

– to provide the opportunity of scientific and/or professional practice (internship) to teachers, staff and students on specialties offered at appropriate institution;

– to carry out mutual reviewing of scientific and methodical work of students and academic teaching staff;

– to facilitate the participation of scientists in work of dissertation councils of Sides in accordance with national legislation;

– to provide assistance in development of academic mobility of students, teachers and staff of Sides with universities and scientific centers of countries of near and far foreign countries, to facilitate enlarging of international cooperation of another Side;

– to inform each other with plans of publishing monographs, scientific research creations, scientific collections;

– to exchange experience in development of progressive methods of education and implementation of system of credit-transfer system.

2.2. It is not excluded that cooperation of Agreeing parties can be arranged in sphere of university policy and administration by organization staff exchange in this activity sphere for experience exchange and interuniversity cooperation results summing up.

3. Other Conditions

3.1. Present Agreement doesn't exclude other forms of cooperation that can be proposed for discussion by initiative of one of the parties, and also might be completed and changed in written form and signed by representatives.

3.2. For realization of statements of present Agreement Agreeing parties can develop and approve new Work programs of cooperation, in which there might be pointed concrete forms, scientific topics, terms and quota of cooperation, and also order and condition of its organization and financing.

4. Conclusive Statements

4.1. Present Agreement will come into force from the Parties signing day and will operate during 5 (five) years, precisely till March 15, 2026.

4.2. Parties can dissolve present Agreement at pre-term period, informing in written form about their intentions

жазбаша түрде хабардар ете отырып, бірақ осы Келісімнің аяқталу күніне дейін үш айдан кешіктірмей осы келісімді бұза алады.

4.3. Кез-келген қызметте туындаған кез-келген дау-дамай жағдайында оны екі тарап та тиісті елдердің белгіленген заңдарын сақтай отырып шешеді.

4.4. Осы Шарт қазақ және ағылшын тілдерінде, Тараптардың әрқайсысы үшін бір (1) данадан бірдей заңды күшке ие екі (2) данада жасалды.


5. Тараптардың заңды мекенжайлары

Д-р Д. Ы. Патил Unitech Қоғамы


Д-р Д. Ы. Патил фармацевтикалық ғылымдар және зерттеулер институты, Пимпри, Пуна, Үндістан – 411018

Тел.: 02067116417/02027805292/02027805293

Институт директоры – д-р Сохан С. Читландж


16/04/2021

Доцент – д-р Р. П. Бhole


16/04/2021

«Академик Е.А. Бөкетов атындағы Қарағанды университеті» КЕ АҚ

Қазақстан Республикасы,

100024, Қарағанды,

Университет көшесі, 28-үй

тел.: +7 7212 356412

факс: +7 7212 356398

E-mail: office@ksu.kz

Сайт: www.buketov.edu.kz

Басқарма төрағасы – ректоры


2021


Дулатбеков Нурлан

other Party, but not later than before three months till present Agreement expiry date.

4.3. In case of any dispute arising in any of activity it will be solved mutually by both of the parties in adherence of the prescribed laws of respective countries.

4.4. This Agreement is made in both Kazakh and English languages in two (2) copies, possessing equal legal power, one (1) copy for each Party.


5. Legal Addresses of Parties

Dr. D. Y. Patil Unitech Society's

Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, India – 411018

Phone: 02067116417/02027805292/02027805293

Principal of the Institute – Dr. Sohan S. Chitlange


16/04/2021

Associate Professor – Dr. R. P. Bhole


16/04/2021

NPLC «Karagandy University of the name of Academician E. A. Buketov»

Republic of Kazakhstan,

100024, Karaganda,

28, Universitetskaya str.


tel.: +7 7212 356412

fax: +7 7212 356398

E-mail: office@ksu.kz

Сайт: www.buketov.edu.kz

Chairman of the Board – Rector


2021


Nurlan Dulatbekov

MEMORANDUM OF UNDERSTANDING

BETWEEN



IVAN FRANKO NATIONAL UNIVERSITY, LVIV

UKRAINE.

AND



DR. D. Y. PATIL INSTITUTE OF

PHARMACEUTICAL SCIENCES AND RESEARCH,

PIMPRI, PUNE-INDIA



MEMORANDUM OF UNDERSTANDING
Between
IVAN FRANKO NATIONAL UNIVERSITY, LVIV, UKRAINE.
and
DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH,
PIMPRI, PUNE-INDIA

In accordance with a mutual desire to promote academic cooperation between **IVAN FRANKO NATIONAL UNIVERSITY, LVIV, UKRAINE** (hereinafter "IFNU") and **DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PIMPRI, PUNE-INDIA** (hereinafter "DPU Pharmacy") the undersigned parties agree to cooperate under the terms of the following agreement.

RECITALS

WHEREAS, IFNU and DPU Pharmacy both have health science-related programs and affiliated health care systems that are involved in biomedical/pharmaceutical/natural product research and the related education of students;

NOW THEREFORE, in contemplation of the mutually beneficial relationships to be established, and in consideration of the mutual promises and covenants contained herein, the sufficiency of which is hereby agreed to and accepted, the Parties agree as follows:

TERMS

Purpose of the MOU: Definition.

- a. The primary objective of this MOU is to create a means for cooperative efforts between IFNU and DPU Pharmacy to affect the academic and research interchange of faculty and students, and academic and research information between the two Institutions.
- b. "Home Institution" refers to the Institution sending its student(s), or faculty member(s) to the other Institution for the purposes of study, learning, teaching and/or research.
- c. "Receiving Institution" refers to the Institution hosting the visiting student(s), or faculty member(s) from the other Institution for the purposes of study, learning, teaching, and/or research.

(Dr. Vasyl S. Matychuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021



(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021

AB Thomas

S. S. Chitlange



ARTICLE I:

IVAN FRANKO NATIONAL UNIVERSITY, LVIV, UKRAINE and DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH, PIMPRI, PUNE-INDIA, agree to promote the following activities to enhance each other's educational, academic, and research activities:

I. Activities such as collaborative research activities

- a) IFNU and DPU pharmacy both agree to undertake joint collaborative research in areas of mutual interest and benefit for both the organizations. The cost of such research projects will be shared amongst both the institutions.
- b) Both the parties also agreed to submit the joint research proposal/s to the funding agencies (if any).
- b) All publications resulting from the research or any other collaboration between the two Institutions shall acknowledge the existence of the collaboration formed under this MOU. Likewise, the relationship between the Parties shall be mentioned in all formal presentations which result from any collaboration formed under this MOU.
- c) Each research project conducted jointly by the Parties shall be made under a formal written research collaboration agreement containing whatever terms the Parties mutually agree are necessary to address the research information and intellectual property that could result from the joint activity of the Parties. All such discussions of the Parties regarding these matters will at all times strive to preserve a harmonious and continuing relationship between the Parties.

(Dr. Vasyl S. Matychuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021

(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021



- d) All research and other activities conducted under this MOU must be conducted in accordance with the laws, rules, and regulations applicable to each Institution. In the case of IFNU, these are the laws, rules, and regulations of the Govt. of Ukraine. In the case of DPU Pharmacy, these are the laws, rules, and regulations of Govt. of India.

2. Joint symposiums, webinars, conferences, workshops and short-term courses.

- a) IFNU and DPU Pharmacy also, agreed to conduct and organize joint symposiums, webinars, conferences, workshops and short-term courses in areas of mutual interest and benefit for both the organizations. The cost of such activities will be shared amongst both the institutions.
- b) Both the parties also agreed to submit the joint proposal/s for conduct of such activities to the funding agencies (if any).
- c) Both the parties agreed to help identify and invite faculty members from the other institution to participate in symposiums, webinars, conferences, workshops and short-term courses. The terms and conditions for such participation will be worked out by mutual agreement between IFNU and DPU Pharmacy.

3. Exchange of faculty members and researchers:

- a) IFNU and DPU Pharmacy will actively seek to promote mutual faculty exchange for mutual agreed periods.
- b) Faculty exchange may assume various forms, such as individual short-time and long term visits of faculties, joint research and development projects.

(Dr. Vasyl S. Matychuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021



(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021



- c) IFNU and DPU Pharmacy will try to seek external funding sources to facilitate these exchanges.
- d) Encouragement of the academic faculty to co-author publications, joint research activities and joint project possibilities is in subject to applicable copyright and / or other laws of each country, as well as rules and regulations of the perspective Institution.
- e) The host institution will endeavor to, as much as possible, make available such facilities that will enable the faculty to obtain experience and training in its departments and institutes, including the use of its laboratories and libraries.
- f) IFNU and DPU Pharmacy acknowledge that in the absence of an external funding agency, all expenses for travel, living and allied costs will be left to the discretion and the responsibility of the home Institution.
- g) Any Intellectual Property developed during the joint activity will be jointly owned by the two Institutions.

4. Student exchange programs in terms of short-term visit and internship:

- a) The aim of the exchange program is to provide students an opportunity to have experience of international cooperation and exchange, as well as to gain a better understanding of Ukraine and India through education.
- b) The term of study for exchange students participating in this program will be mutually decided by two parties.

(Dr. Vasyl S. Matychuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021



(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021

ABT

S. S. Chitlange



- c) IFNU and DPU Pharmacy also agree to accommodate the students in the academic programs available in both the institution (PG/ PhD) in condition to meet all applicable regulatory and admission standards of the Receiving Institution and obtain all required approvals from the Home Institution for participation in a Program. These standards include but are not limited to requirements for language proficiency; medical training and experience; license (if required); professional liability insurance as applicable; personal health and travel insurance; vaccinations; VISA applications and other necessary governmental approvals or permissions.
- d) The host university shall reserve or make available accommodation on campus or assist them to make alternative arrangement.
- e) Any Intellectual Property developed during the joint activity will be jointly owned by the two Parties.

ARTICLE 2:

Matters pertaining to the implementation of the exchange based on this agreement shall be negotiated and agreed upon by representatives of the two parties.

ARTICLE 3:

None of the parties shall use the name, logo, likeness, trademarks, image or other intellectual property of either of the other parties for any advertising, marketing, endorsement or any other purposes without the specific prior written consent of an authorized representative of the other party as to each such use.

(Dr. Vasyl S. Matiyehuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021




(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021

AB Thomas

S. S. Chitlange



ARTICLE 4:

This agreement shall become effective on the date of which it has been signed by both parties, and it shall be in force for five years. Revision and modification of the agreement may be implemented by mutual agreement of both signatories subject to a six-month minimum notification period prior to the expiration of the existing agreement. Either party may terminate this agreement at any time with a six-month notice in advance.

The renewal of this agreement shall be discussed by both parties no less than six months prior to the expiration of this agreement.

ARTICLE 5:

This agreement is to be executed by joint signature of two identical copies, written in English with each party retaining one copy.

(Dr. Vasyl S. Matyichuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv,
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021



(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA

Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head

Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA

Date 18/3/2021



- c) IFNU and DPU Pharmacy will try to seek external funding sources to facilitate these exchanges.
- d) Encouragement of the academic faculty to co-author publications, joint research activities and joint project possibilities is in subject to applicable copyright and / or other laws of each country, as well as rules and regulations of the perspective Institution.
- e) The host institution will endeavor to, as much as possible, make available such facilities that will enable the faculty to obtain experience and training in its departments and institutes, including the use of its laboratories and libraries.
- f) IFNU and DPU Pharmacy acknowledge that in the absence of an external funding agency, all expenses for travel, living and allied costs will be left to the discretion and the responsibility of the home Institution.
- g) Any Intellectual Property developed during the joint activity will be jointly owned by the two Institutions.

4. Student exchange programs in terms of short-term visit and internship:

- a) The aim of the exchange program is to provide students an opportunity to have experience of international cooperation and exchange, as well as to gain a better understanding of Ukraine and India through education.
- b) The term of study for exchange students participating in this program will be mutually decided by two parties.


(Dr. Vasyl S. Matychuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021



(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021



- c) IFNU and DPU Pharmacy also agree to accommodate the students in the academic programs available in both the institution (PG/ PhD) in condition to meet all applicable regulatory and admission standards of the Receiving Institution and obtain all required approvals from the Home Institution for participation in a Program. These standards include but are not limited to requirements for language proficiency; medical training and experience; license (if required); professional liability insurance as applicable; personal health and travel insurance; vaccinations; VISA applications and other necessary governmental approvals or permissions.
- d) The host university shall reserve or make available accommodation on campus or assist them to make alternative arrangement.
- e) Any Intellectual Property developed during the joint activity will be jointly owned by the two Parties.

ARTICLE 2:

Matters pertaining to the implementation of the exchange based on this agreement shall be negotiated and agreed upon by representatives of the two parties.

ARTICLE 3:

None of the parties shall use the name, logo, likeness, trademarks, image or other intellectual property of either of the other parties for any advertising, marketing, endorsement or any other purposes without the specific prior written consent of an authorized representative of the other party as to each such use.

(Dr. Vasyl S. Matiyehuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021




(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA
Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head
Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA
Date 18/3/2021

AB Thomas

S. S. Chitlange



ARTICLE 4:

This agreement shall become effective on the date of which it has been signed by both parties, and it shall be in force for five years. Revision and modification of the agreement may be implemented by mutual agreement of both signatories subject to a six-month minimum notification period prior to the expiration of the existing agreement. Either party may terminate this agreement at any time with a six-month notice in advance.

The renewal of this agreement shall be discussed by both parties no less than six months prior to the expiration of this agreement.

ARTICLE 5:

This agreement is to be executed by joint signature of two identical copies, written in English with each party retaining one copy.

(Dr. Vasyl S. Matyichuk)
Professor
Department of Organic Chemistry, Ivan Franko
National University, Lviv
UKRAINE
Date 16.03.2021

Dr. Hryhoriy S. Dmytriv,
Dean of Faculty of Chemistry,
Ivan Franko National University, Lviv
UKRAINE
Date 16.03.2021



(Dr. A. B. Thomas)
Professor and H.O.D. Department of Pharmaceutical
Chemistry
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and
Research Pune
INDIA

Date 18/3/2021

(Dr. S. S. Chitlange)
Principal & Head

Dr. D. Y. Patil Institute of Pharmaceutical Sciences
and Research Pune
INDIA

Date 18/3/2021



**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18**

**Facility Creation for Research
(Installation reports for new faculty created)**

Installation Report for Interchim Flash 5.250 Automated Chromatography system



**SPINCO BIOTECH
PVT LTD**
since 1981

BRINDING TECHNOLOGY ENABLING SCIENCE

Head office: 'Spinco Towers' 81-84, Perungudi Industrial Estate, Perungudi, Chennai - 600096. Phone No. 044-45678900
Email: chennai@spincotech.com Web: www.spincotech.com

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18**

Installation Report for •Freeze Dryer/Lyophilizer

	LABMATE (ASIA) PVT. LTD. BAID MEHTA COMPLEX, C- BLOCK, 1ST FLOOR, NO 16 (OLD NO. 183), MOUNT ROAD, SAIDAPET, CHENNAI - 15. INDIA. TEL : 044-2220 0066 / 2220 0166 E-mail : customersupport@labmateasia.com / sales@labmateasia.com Website : www.labmateasia.com	Customer Copy ☒
		Office Copy
INSTALLATION / SERVICE REPORT		
Customer : <u>Dr D.Y. Patil College</u>		Product : <u>Christ</u>
Address : <u>Sant Tukaram Nagar</u> <u>Pimpri Pune - 411018</u>		Serial No. : <u>27728</u>
Contact Person : <u>Sarjeevoni . D</u>		Model : <u>S.W. Ver.</u> <u>Alpha 2-4/SC Basic</u>
Phone : <u>9850547454</u> Fax :		Date(s) of Visit : <u>3/6/2021</u>
Department : <u>Pharma</u>		Job Completed : Yes ☒ No ☐
Reasons For ☒ Installation ☐ Warranty ☐ Service Contract ☐ Paid Service		
Visit ☐ Free Service ☐ Inspection ☐ Customer Training ☐ Others		
Description of Works <u>Installation Report</u>		
* Checked the consignment found no short shipment all according to P.O. no damage * Installed the unit, vacuum pump, Chamber, sensor, solenoid valve etc. * Took the trial of the instrument ice condensor reached to -81°C and achieved the desired vacuum of 0.05m * Connected the new 3pin top and checked supply found OK & connected to UPS. * System working OK. * Training explain <u>done</u> * Demonstration given to users successfully.		
Customer's Signature & Seal		Engineer's Signature <u>A</u> Date : <u>3/6/21</u>
Customer Name : <u>Dr. S.S. Deshpande</u> <u>Amish Ahir</u>		

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18**

Installation Report for Deep Freezer (-80°C)

REMI SALES & ENGINEERING LIMITED														
3rd Floor, Patel House, 11, Camra Ind. Estate, Goregaon (E), Mumbai - 400063. Service Helpline No. 7040607005, Bypass - +91 22 40506050. Fax No.: +91 22 40506050 Email: service@remisales.com Website: www.remisales.com														
SR.NO:														
REMI GROUP		SERVICE REPORT												
Service Visit Report of Mr. <u>Sudhir Shinde</u>		Division: Service		HQ: Mumbai		Mobile No. <u>9524914269</u>		COMPLAINT No. <u>0901141</u> COMPLAINT DATE: _____						
Date: <u>6/4/2021</u>		Start Time: Home / Office / Customer		Completion Registration form attached		Left Time: <u>14:40</u>		Arrival time at Customer: <u>15:30</u>		Left time from customer:		Arrival time at Home/Office:		
Details of Customer:		Service Instrument Details		Service Rendered under:		Spare Replaced		Spare Rejected		Chargeable		Yes ☐ No ☐		
Name: <u>DR. D.Y. Patil collage of Pharmacy, Pimpri - Pune</u>		Name: <u>ULT-200</u>		1) ABC ☐ 2) CWC ☐		3) ABC ☐ 4) CWC ☐		5) ABC ☐ 6) CWC ☐		7) ABC ☐ 8) CWC ☐		9) ABC ☐ 10) CWC ☐		
Model No.: <u>ULT-185</u>		Model No.: <u>ULT-185</u>		1) Installation ☒ 2) Calibration ☐		3) Calibration ☐ 4) Warranty ☐		5) Calibration ☐ 6) Warranty ☐		7) Calibration ☐ 8) Warranty ☐		9) Calibration ☐ 10) Warranty ☐		
Warranty: <u>12021</u>		Warranty: <u>12021</u>		1) Calibration ☐ 2) Warranty ☐		3) Calibration ☐ 4) Warranty ☐		5) Calibration ☐ 6) Warranty ☐		7) Calibration ☐ 8) Warranty ☐		9) Calibration ☐ 10) Warranty ☐		
Mobile No. / Email / Phone No.: <u>9850547454</u>		Voltage: <u>235V</u>		Capacity (KWH): <u>10.0</u>		Voltage: <u>235V</u>		Capacity (KWH): <u>10.0</u>		Voltage: <u>235V</u>		Capacity (KWH): <u>10.0</u>		
Actual name of Supplier (after verification of invoice or without):		Name: <u>Remi</u>		Line Voltage: <u>235V</u>		Output Voltage: <u>232V</u>		Calibration Done: ☐		Calibration Done: ☐		Calibration Done: ☐		
Actual Fault Observed in Instrument:		Installation & Demo		Actual Fault Observed in Instrument:		Actual Fault Observed in Instrument:		Actual Fault Observed in Instrument:		Actual Fault Observed in Instrument:		Actual Fault Observed in Instrument:		
Complaint Description:		Operational Deficiency ☐ Equipment Deficiency ☐		Complaint Description:		Complaint Description:		Complaint Description:		Complaint Description:		Complaint Description:		
Details of Service Rendered:		Installation & Demo. done completed. Checked the work as per set temp. -80°C found working satisfactory.		Details of Service Rendered:		Details of Service Rendered:		Details of Service Rendered:		Details of Service Rendered:		Details of Service Rendered:		
Service Engineer Remarks:		Service Engineer Remarks:		Service Engineer Remarks:		Service Engineer Remarks:		Service Engineer Remarks:		Service Engineer Remarks:		Service Engineer Remarks:		
Any Critical Observation:		Any Critical Observation:		Any Critical Observation:		Any Critical Observation:		Any Critical Observation:		Any Critical Observation:		Any Critical Observation:		
Customer Remarks:		Customer Remarks:		Customer Remarks:		Customer Remarks:		Customer Remarks:		Customer Remarks:		Customer Remarks:		
Service Engineer's Name: <u>Sudhir Shinde</u>		Service Engineer's Name: <u>Sudhir Shinde</u>		Service Engineer's Name: <u>Sudhir Shinde</u>		Service Engineer's Name: <u>Sudhir Shinde</u>		Service Engineer's Name: <u>Sudhir Shinde</u>		Service Engineer's Name: <u>Sudhir Shinde</u>		Service Engineer's Name: <u>Sudhir Shinde</u>		
Service Engineer's Signature: <u>[Signature]</u>		Service Engineer's Signature: <u>[Signature]</u>		Service Engineer's Signature: <u>[Signature]</u>		Service Engineer's Signature: <u>[Signature]</u>		Service Engineer's Signature: <u>[Signature]</u>		Service Engineer's Signature: <u>[Signature]</u>		Service Engineer's Signature: <u>[Signature]</u>		
Service Dept. Remark with Signature:		Service Dept. Remark with Signature:		Service Dept. Remark with Signature:		Service Dept. Remark with Signature:		Service Dept. Remark with Signature:		Service Dept. Remark with Signature:		Service Dept. Remark with Signature:		
Sales Dept. Remark with Signature:		Sales Dept. Remark with Signature:		Sales Dept. Remark with Signature:		Sales Dept. Remark with Signature:		Sales Dept. Remark with Signature:		Sales Dept. Remark with Signature:		Sales Dept. Remark with Signature:		



**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18**

**Installation and Service Report for Pure C-810 Automated Flash Chromatography
system**

BUCHI India
Private Limited

201, Magnum Opus
Shantinagar Industrial Area
Vakola, Santacruz (East)
Mumbai 400 055

T +91 22 6677 54 00
F +91 22 6671 89 86
india@buchi.com
www.buchi.com

D.Y. Patil Institute of Pharmaceutical Sciences &
Research,
Pharmaceutics
Sant Tukaram Nagar, Pimpri
Pune 411018
Maharashtra

Service Report

S109628

Customer Number: A237146
Customer Inquiry: Ritesh Bhole
Customer order Number:

Date: 9/1/2021
Service Engineer: Prashant Poojary
Phone: +91 96571 03927
E-Mail: poojary.p@buchi.com
Contract:



Case No: CAS-137825-W7S6G7
Description: C-810 - Demo and Training

We have conducted training for the operation of C-810 Pure system to all faculty. Given complete instrument demonstration for the operation and maintenance procedure to all users. Also run the customer's sample of natural product and found the result was satisfactory. Now the system is ready for use.

Pos	Description	Qty	Unit	Invoice Rule
	Serial Number		Device	
	1100081455		C-810 Flash basic	
	Time and Expenses:			
	External working hours		h	
	Internal working hours		h	
	Travel time		h	

Confirmation:

Customer:


Service Engineer:

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18**

Installation and Service Report for Radleys Parallel Synthesizer

VISIT REPORT * Installation Report *		inkarp®	
Customer Name:	Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research	Report No.:	GS-0012362
Site / Dept:	chemistry	Visit Dates:	07/07/2021
Address: Sant Tukaram Nagar Pimpri		☒ Installation	☐ Down Call ☐ PM
City:	Pune	☐ Demo	☐ Courtesy ☐ Others
Contact:	Dr. Ritesh Bhole	☐ Warranty	☐ AMC ☐ CMC ☐ Chargeable
Designation:	Professor	Warranty/AMC/CMC Start Date:	07/07/2021
Email:	ritesh.bhole@dypp.edu.in	Warranty/AMC/CMC End Date:	06/07/2021
Phone:	9890904939.	Engineer Details:	Mukesh Mahajan 9763336527
Principal Name:	Radleys	Email:	service@inkarp.co.in
Product:	Parallel Synthesizer	PO No. / Date:	003/03/MAR Date: 10/05/2021
Model:	6 PLUS Carrousel	Invoice No. / Date:	INV/21-22/1018 Date: 19/06/2021
Serial No.:	200417913		
Other Components:			
Details of Work Done: * Opened the consignment & received the instrument as per PO. * Installed & demonstrated the operational performance of the instrument. * Now the instrument is found working satisfactorily.			
Parts Required / Replaced: - N/A -			
Persons Trained: Dr. Ritesh Bhole.			
Customer Remarks: found working properly			
Engineer Remarks:			
Customer Seal with Signature: (Signature of Dr. Ritesh Bhole)		Engineer Signature (Signature of Mukesh Mahajan)	

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

Intensified Collaborative Research Activities
(Joint Patents and Research Publications)

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202021043105 A

(19) INDIA

(22) Date of filing of Application :05/10/2020

(43) Publication Date : 27/11/2020

(54) Title of the invention : **NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS AND HERBAL MEDICINES**

(51) International classification	:A61K	(71)Name of Applicant :
(31) Priority Document No	31/00	1)Dr. D. Y. Patil Unitech Society™s Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research
(32) Priority Date	:NA	Address of Applicant :Dr. D. Y. Patil Unitech Society™s Dr.
(33) Name of priority country	:NA	D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant
(86) International Application No	:NA	Tukaram Nagar, Pimpri, Pune-411 018 Maharashtra India
Filing Date	:NA	(72)Name of Inventor :
(87) International Publication No	: NA	1)Dr. Sohan S. Chitlange
(61) Patent of Addition to Application Number	:NA	2)Dr. Dheeraj H. Nagore
Filing Date	:NA	3)Pooja F. Kauthale
(62) Divisional to Application Number	:NA	4)Rakesh S. Shivatare
Filing Date	:NA	

(57) Abstract :

The present invention relates to a novel composition of Nanotechnology-Based Drug Delivery Systems i.e. Liquorice (Glycyrrhiza glabra), Manjishta (Rubia cordifolia), Tulsi (Ocimum sanctum), Jayphala (Myristica fragrans), Nagkesar (Mesua ferrea) and sesame oil. More specifically it relates to the field of method of preparation of topical dosage form based on nano technology having therapeutic properties. Further more specifically, it relates to Nanotechnology-Based Drug Delivery Systems based topical synergistic herbal formulations which are effective against wrinkle and other skin disorder, along with process for the preparation of the same in pharmaceutical acceptable dosage forms.

No. of Pages : 22 No. of Claims : 3

FORM 5
THE PATENTS ACT, 1970
(39 of 1970)
&
The Patents Rules, 2003
DECLARATION AS TO INVENTORSHIP
[See section 10(6) and rule 13(6)]

1. NAME OF APPLICANTS

We,

Name of inventor	Address	Country
Dr. D. Y. Patil Unitech Society's Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research	Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant Tukaram Nagar, Pimpri, Pune-411 018	India

Hereby declare that the true and first inventor(s) of the invention disclosed in the complete specification filed for our invention related "NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS AND HERBAL MEDICINES" are,

2. INVENTORS

Name of inventor	Address	Nationality
Dr. Sohan S. Chitlange	Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant Tukaram Nagar, Pimpri, Pune- 411 018	Indian
Dr. Dheeraj H. Nagore	Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant Tukaram Nagar, Pimpri, Pune- 411 018	Indian
Pooja F. Kauthale	Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant Tukaram Nagar, Pimpri, Pune- 411 018	Indian
Rakesh S. Shivatare	Aayush Healthcare Office No 501, Crossroad, Wakad, Pune, Maharashtra, 411057	Indian

Dated this 04th October, 2020

For Applicants:

(Signed) 
MAHESH MADANRAO ADHAV
(IN/PA/2087)

3. DECLARATION TO BE GIVEN WHEN THE APPLICATION IN INDIA IS FILED BY THE APPLICANT (S) IN THE CONVENTION COUNTRY:

We the applicant(s) in the convention country hereby declare that our right to apply for a patent in India is by way of assignment from the true and first inventor(s).

Dated thisday of 20.....

Signature

Name of the signatory

4. STATEMENT (to be signed by the additional inventor(s) not mentioned in the application form)

We assent to the invention referred to in the above declaration, being included in the complete specification filed in pursuance of the stated application.

Dated thisday of 20.....

Signature of the additional inventor (s)

Name of the signatory

To,
The Controller of Patents
The Patent Office Branch, Mumbai

**Shivani Desai¹, Ramesh R. Bhonde²,
Sameer S. Parekh³**

¹Department of Pharmacology, Dr. D. Y. Patil
 Institute of Pharmaceutical Sciences and
 Research, Pune; ²Dr. D. Y. Patil Vidyapeeth, Pune;
³Serum Institute of India, Pune, India

Received: September 11, 2020
 Accepted: January 25, 2021

Corresponding author: Shivani Desai, PhD
 Dr. D. Y. Patil Institute of Pharmaceutical Sciences
 and Research, Sant Tukaram Nagar, Pimpri, Pune,
 India
 Tel: +91-9638959797, Fax: +91-2027805293
 E-mail: shivani.desai@dyvp.edu.in

No potential conflict of interest relevant to this
 article was reported.

The authors are thankful to the Principal, Dr.
 Sohan S. Chitlange, and the management of Dr.
 D. Y. Patil Institute of Pharmaceutical Sciences
 and Research, Pune. The authors are also obliged
 to Dr. D. Y. Patil Vidyapeeth, Pune; and Serum
 Institute of India, Pune for extending continuous
 support and motivation to write this hypothesis.

© Korean Vaccine Society.

This is an Open Access article distributed under the
 terms of the Creative Commons Attribution Non-Com-
 mercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial
 use, distribution, and reproduction in any medium, pro-
 vided the original work is properly cited.

Polyvaccine: joining the links in the cascade of type 1 diabetes

The incidence of type 1 diabetes mellitus (T1DM), an autoimmune disorder, has ascended considerably with around 98,200 and 15,900 incidents in children below 15 years of age, globally and in India, respectively. This is typically due to environmental changes leading to genetic modifications. Also, T1DM encompasses the presence of autoantigens and many other etiologies which can be targeted by proper immunization. In this paper, we consciously discuss and collate various candidate triggers of islet autoimmunity and other factors expected to promote progression of T1DM. This paper bridges all the mechanisms caused by these factors and linking them with each other. We have also highlighted on the novel corona virus as a trigger for T1DM. Finally, we suggest that an amalgamated model of polyvaccine can batter the condition by inducing protection against various triggers of T1DM.

Keywords: Type 1 diabetes mellitus, Viruses, Coronavirus, Cow's milk, Hybrid insulin peptides, Vaccines

Introduction

Diabetes mellitus is caused either by insulin deficiency or insulin resistance, and sometimes a combination of both. Insulin deficiency may be caused due to pancreatitis, pancreatectomy, alcoholic chronic pancreatitis, cystic fibrosis, hemochromatosis, mitochondrial DNA mutations, leprechaunism, lipoatrophy, autoimmune diseases, glucagonoma, acromegaly, pheochromocytoma, thyroid disease, Cushing's syndrome, and/or by drugs and toxins. This is the cause for type 1 diabetes mellitus (T1DM) which by nature may be autoimmune or idiopathic. The combination of insulin deficiency and insulin resistance may cause type 2 diabetes mellitus (T2DM) or gestational diabetes. In contrast to T2DM, T1DM shows acute presentation with prediabetes as the phase before its onset which provides a window for early intervention [1].

Globally, a total of 600,900 children and adolescents below 15 years of age are estimated to suffer from T1DM and 98,200 children and adolescents of the same age group are diagnosed with T1DM every year. Among these, India witnesses 95,000 children and adolescents below 15 years with T1DM, with an incidence of 15,900. The complications caused due to T1DM, affects the quality of life in patients and even after a proper diagnosis it may cause mortalities in the countries with insufficient health service provisions [2]. The expenses for the medical treatment of T1DM are high [3]. In this



Research Article

Herb drug interaction of *Tinospora cordifolia* (Willd.) Miers extract and Glimepiride: *In vivo* and *in silico* studies

Asha B. Thomas^{1*}, Aaftab S. Shaikh¹, Amol Raje², Kiran B. Lokhande³, K. Venkateswara Swamy³, Dheeraj H. Nagore⁴ and Rohit Dake⁵

¹Department of Pharmaceutical Quality Assurance, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, Maharashtra, India

²Clinical Candidate Optimization Department, Advinus Therapeutics Limited, Pune, Maharashtra, India

³Bioinformatics Research Laboratory, Dr. D.Y. Patil Biotechnology and Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra, India

⁴Department of Pharmacognosy, ⁵Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, Maharashtra, India

Received: September 11, 2020; Accepted: November 03, 2020

ABSTRACT

Tinospora cordifolia (Willd.) Miers (TC), family *Menispermaceae* is a well-known traditional herb reported in traditional Indian literature for the treatment of various disorders such as diabetes and cardiovascular diseases. Berberine, the chief active constituent of TC is reported to possess anti-diabetic potential along with other isoquinoline alkaloids. TC and its active constituent berberine both have been reported to be potent CYP2C9 inhibitor, thereby raising herb drug interaction (HDI) potential on co-administration with drugs metabolized through the CYP pathway. The present study evaluated the pharmacokinetic HDI of TC hydroalcoholic extract with Glimepiride (GP) after oral co-administration in Wistar rats using *in vivo* pharmacokinetic and *in silico* studies. After oral co-administration of TC extract (100 mg/kg) with GP (20 mg/kg) in rats, drug concentrations in plasma were determined using HPLC method. The main pharmacokinetic parameters of C_{max} , T_{max} , AUC, Vd, CL, and MRT_{0-t} were calculated using Win Nonlin software. Also *in silico* molecular docking study using CYP2C9 (PDB ID: 1R90) as target protein and phytoconstituents (isoquinoline alkaloids) of TC as ligands were carried out using AutoDock Vina 1.1.2 to determine their CYP2C9 interaction potential. The PK interactions studies demonstrated an increase in the systemic levels of GP. A significant increase in C_{max} , AUC_{0-t} and MRT_{0-t} of GP ($p < 0.01$) was observed, along with a substantial decrease in Vd and CL. *In silico* molecular docking studies on CYP2C9 demonstrated high inhibition potential of berberine (binding affinity: -9.6 kcal/mol) with formation of two hydrogen bonds with Ser 209 and Asn 474 in the active site of enzyme, complementing the literature reports as well as our *in vivo* PK findings. The results obtained from *in vivo* and *in silico* studies proposed that, for a co-administration of GP and TC extract, there exists a potentially significant PK HDI. This knowledge concerning potential HDI of GP might prove helpful for healthcare professionals as well as diabetic patients on GP therapy. It eventually warrants further studies to predict the pharmacokinetics and pharmacodynamics of GP in humans in case of HDI.

Keywords: Berberine, giloe, glimepiride, herb-drug interaction, HPLC-PDA

Abbreviations: ANOVA = Analysis of variance; AUC 0-∞ = Area under plasma concentration-time curve extrapolated to infinity; AUC_{0-t} = Area under plasma concentration-time curve from zero to last time point; CL = Plasma clearance; C_{max}

*Corresponding author e-mail: asha.thomas@dypvp.edu.in



Australian Government

IP Australia

CERTIFICATE OF GRANT INNOVATION PATENT

Patent number: 2021103977

The Commissioner of Patents has granted the above patent on 25 August 2021, and certifies that the below particulars have been registered in the Register of Patents.

Name and address of patentee(s):

C.G. Bonde of SVKMs NMIMS, School of pharmacy and tech. Management Shirpur, Dist. Dhule Maharashtra India

R. P. Bhole of Dr. D. Y. Patil Institute of, Pharmaceutical Sciences and Research Pimpri, Pune Maharashtra India

Rupesh V. Chikhale of UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX London United Kingdom

Title of invention:

SYNTHESIS OF NOVEL ANTITUBERCULAR AGENTS

Name of inventor(s):

Bonde, Smita; Sharma, Mayank; Balaramnavar, Vishal M.; B., Satish; Shirode, Abhay Ramchandra; Pant, Amit Madhaorao; Singh, Sushma and Tiwari, Paras

Term of Patent:

Eight years from 8 July 2021

NOTE: This Innovation Patent cannot be enforced unless and until it has been examined by the Commissioner of Patents and a Certificate of Examination has been issued. See sections 120(1A) and 129A of the Patents Act 1990, set out on the reverse of this document.



Dated this 25th day of August 2021

Commissioner of Patents

PATENTS ACT 1990

The Australian Patents Register is the official record and should be referred to for the full details pertaining to this IP Right.

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202111002831 A

(19) INDIA

(22) Date of filing of Application :21/01/2021

(43) Publication Date : 12/02/2021

(54) Title of the invention :DISCOVEY OF IMATINIB A DRUG FOR TREATING CORONAVIRIDAE FAMILY OF VIRUS•

(51) International classification	:G16C0020500000, G16B0035000000, G16C0020600000, G16B0015000000, G16C0020400000	(71)Name of Applicant : 1)Dr. Vishal M. Balaramnavar Address of Applicant :Sanskriti University, School of Pharmacy, 28 K. M. Store, Mathura Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin 281401 Uttar Pradesh India (72)Name of Inventor : 1)Dr. Vishal M. Balaramnavar 2)Dr. Khurshid Ahmad 3)Dr. M. M. Gupta 4)Dr. Swayam Prakash Srivastava 5)Dr Rohit Srivastava 6)Dr Anil Ahuja 7)Dr Mohd Saeed, 8)Dr Umashankar Sharma 9)Dr Yogendra Kumar 10)Pratap Singh Rathore 11)Amit Kumar Sharma 12)Dr. Chandrakant Bonde 13)Dr. Smita Bonde 14)Dr. Ritesh Bhole 15)Dr Sanjay B Bari 16)Dr Ahmad Almatroudi 17)Dr Mohd Adnan Kausar
(31) Priority Document No	:NA	
(32) Priority Date	:NA	
(33) Name of priority country	:NA	
(86) International Application No	:NA	
Filing Date	:NA	
(87) International Publication No	: NA	
(61) Patent of Addition to Application Number	:NA	
Filing Date	:NA	
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :

A method (300) for identifying a binding site of an Imatinib drug, the method comprising;developing pharmacophore models to extract features from the Imatinib drug;validating the developed pharmacophore models by comparing with pre-defined models of existing coronavirus drugs;performing a ligand-based virtual screening (first virtual screening) of a database of drugs with the validated pharmacophore models; performing a structure-based virtual screening (second virtual screening) of the validated pharmacophore models by structural docking of a target protein into the validated pharmacophore models; assigning a score to each pharmacophore model of the Imatinib drugin order to identify the validated pharmacophore models with a high binding affinity and efficiency; and comparing the score obtained from the ligand-based virtual screening (first virtual screening) and the structure-based virtual screening (second virtual screening) for classifying the scored pharmacophore models based on the target protein binding affinity and efficiency for the coronaviridae family of virus.

No. of Pages : 24 No. of Claims : 10

(54) Title of the invention : DISCOVERY OF (3S,4R)-4-(4-FLUOROPHENYL)-1-METHYL-3((TRITYLOXY)METHYL)PIPERIDINE FOR TREATING TUBERCULOSIS

(51) International classification :G16C0020500000, G16B0035000000, G16C0020600000, G16B0015000000, G16C0020400000 (31) Priority Document No :NA (32) Priority Date :NA (33) Name of priority country :NA (86) International Application No :NA Filing Date :NA (87) International Publication No : NA (61) Patent of Addition to Application Number :NA Filing Date :NA (62) Divisional to Application Number :NA Filing Date :NA	(71)Name of Applicant : 1)Dr. Vishal M. Balaramnavar Address of Applicant :Dr. Vishal M. Balaramnavar Sanskriti University, School of Pharmacy, 28 K. M. Stone, Mathura Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin 281401 Email id: v.balaramnavar@gmail.com tmindia123@gmail.com Maharashtra India (72)Name of Inventor : 1)Dr. Vishal M. Balaramnavar 2)Mukesh Masand 3)Dr. Swayam Prakash Srivastava 4)Dr Rohit Srivastava 5)Deepti Mathpal 6)Dr. M. M. Gupta 7)Himanshu Chopra 8)Manish Kumar Shakya 9)Talveer Singh 10)Dr Lalit Kumar Tyagi 11)Dr. Khurshid Ahmad, 12)Prof Pramod Kumar Sharma 13)Dr. Chandrakant Bonde 14)Dr. Smita Bonde 15)Dr. Ritesh Bhole 16)Dr Sanjay B Bari 17)Mohit Kumar Goyal 18)Abhishek Agrawal 19)Bhupinder Bhyan
--	--

(57) Abstract :

A method (300) for identifying a binding site of an Active drug, the method comprising:developing pharmacophore models to extract features from the Active drug;validating the developed pharmacophore models by comparing with pre-defined models of existing tuberculosis drugs;performing a ligand-based virtual screening (first virtual screening) of a database of drugs with the validated pharmacophore models; performing a structure-based virtual screening (second virtual screening) of the validated pharmacophore models by structural docking of a target protein into the validated pharmacophore models; assigning a score to each pharmacophore model of the Active drug in order to identify the validated pharmacophore models with a high binding affinity and efficiency.

No. of Pages : 22 No. of Claims : 10

FORM 1 THE PATENTS ACT 1970 (39 of 1970) and THE PATENTS RULES, 2003 APPLICATION FOR GRANT OF PATENT (See section 7, 54 and 135 and sub-rule (I) of rule 20)				(FOR OFFICE USE ONLY)	
				Application No:	
				Filing date:	
				Amount of Fee paid:	
				CBR No:	
				Signature:	
1. APPLICANT'S REFERENCE / IDENTIFICATION NO. (AS ALLOTTED BY OFFICE)					
2. TYPE OF APPLICATION [Please tick(✓) at the appropriate category]					
Ordinary (✓)		Convention ()		PCT- NP ()	
Divisional ()	Patent of Addition ()	Divisional ()	Patent of Addition ()	Divisional ()	Patent of Addition ()
3A. APPLICANT(S)					
Name in Full		Nationality	Country of Residence	Address of the Applicant	
Dr. Vishal M. Balaramnavar		Indian	India	Sanskriti University, School of Pharmacy, 28 K. M. Stone, Mathura – Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin – 281401	
3B. CATEGORY OF APPLICANT [Please tick (✓) at the appropriate category]					
Natural Person (✓)		Other than Natural Person			
		Small Entity ()	Startup ()	Others ()	
4. INVENTOR(S) [Please tick (✓) at the appropriate category]					
Are all the inventor(s) same as the applicant(s) named above?		YES ()		No (✓)	
If "No", furnish the details of the inventor(s)					
Name in Full		Nationality	Address of the Inventor		
Dr. Vishal M. Balaramnavar		India	Sanskriti University, School of Pharmacy, 28 K. M. Stone, Mathura – Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin – 281401		

Dr. Khurshid Ahmad,	Republic of Korea	Assistant Professor, Department of Medical Biotechnology, Yeungnam University (Yu), Republic of Korea
Dr. M. M. Gupta	West Indies	Dr. M. M. Gupta School of Pharmacy Faculty of Medical Sciences, The University of The West Indies, St. Augustine, Trinidad & Tobago,
Dr. Swayam Prakash Srivastava	USA	Department of Pediatrics 333 Cedar Street, School of Medicine Yale University CT, New Haven CT USA 06511
Dr Rohit Srivastava	Israel	Department of Endocrinology, Laboratory of Medical Transcriptomics, Nephrology Services, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Dr Anil Ahuja	India	Sanskriti University, School of Pharmacy, 28 K. M. Stone, Mathura – Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin – 281401
Dr Mohd Saeed,	India	S-153, Department Of Biology, College Of Sciences, University of Hail, Hail, Saudi Arabia-2440
Dr Umashankar Sharma	India	Director Sri Madanlal Khurana Group of Institutions, Etawah, Uttar Pradesh, India
Dr Yogendra Kumar	India	Professor and HOD, Sanjay College of Pharmacy, Mathura Uttar Pradesh, India
Pratap Singh Rathore	India	Associate Professor, Sanskriti University, School of Pharmacy, 28 K. M. Stone, Mathura – Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin – 281401
Amit Kumar Sharma	India	Principal Salasar Balaji Institute of Pharmacy, Sikar, Rajasthan, India
Dr. Chandrakant Bonde	India	"SVKM's NMIMS, Shirpur Campus Mukesh Patel Technology Park, Babulde, Bank of Tapi River, Mumbai-Agra Road (NH3), Shirpur - 425405, Dist. Dhule, Maharashtra, India. "
Dr. Smita Bonde	India	"SVKM's NMIMS, Shirpur Campus

		Mukesh Patel Technology Park, Babulde, Bank of Tapi River, Mumbai-Agra Road (NH3), Shirpur - 425405, Dist. Dhule, Maharashtra, India. "
Dr. Ritesh Bhole	India	"Dr. D. Y. Patil Unitech Society Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Sant Tukaram Nagar, Pimpri, Pune 411018 Maharashtra, India"
Dr Sanjay B Bari	India	Prof. Dr. S. B. Bari Principal, H R Patel institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India
Dr Ahmad Almatroudi	Saudi Arabia	Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51431, Saudi Arabia
Dr Mohd Adnan Kausar	Saudi Arabia	Assistant Professor, Department fo Biochemistry, College of Medicine, University of Hail, KSA,
5. TITLE OF THE INVENTION		
"DISCOVEY OF IMATINIB A DRUG FOR TREATING CORONAVIRIDAE FAMILY OF VIRUS"		
6. AUTHORISED REGISTERED PATENT AGENT(S)	IN/PA No.	2087
	Name	Mahesh Madanrao Jadhav
	Mobile No.	7083086554
7. ADDRESS FOR SERVICE OF APPLICANT IN INDIA	Dr. Vishal M. Balaramnavar Sanskriti University, School of Pharmacy, 28 K. M. Stone, Mathura – Delhi Highway, Chhata, Mathura Uttar Pradesh (U.P.) Pin – 281401 Email id: v.balaramnavar@gmail.com tmindia123@gmail.com	
8. IN CASE OF APPLICATION CLAIMING PRIORITY OF APPLICATION FILED IN CONVENTION COUNTRY, PARTICULARS OF CONVENTION APPLICATION		

Country	Application Number	Filing date	Name of the applicant	Title of the invention	IPC (as classified in the convention country)
9. IN CASE OF PCT NATIONAL PHASE APPLICATION, PARTICULARS OF INTERNATIONAL APPLICATION FILED UNDER PATENT CO-OPERATION TREATY (PCT)					
International application number			International filing date		
10. IN CASE OF DIVISIONAL APPLICATION FILED UNDER SECTION 16, PARTICULARS OF ORIGINAL (FIRST) APPLICATION					
Original (first) application No.			Date of filing of original (first) application		
11. IN CASE OF PATENT OF ADDITION FILED UNDER SECTION 54, PARTICULARS OF MAIN APPLICATION OR PATENT					
Main application/patent No.			Date of filing of main application		
12. DECLARATIONS					
(i) Declaration by the inventor(s) (In case the applicant is an assignee: the inventor(s) may sign herein below or the applicant may upload the assignment or enclose the assignment with this application for patent or send the assignment by post/electronic transmission duly authenticated within the prescribed period). I/We, the above named inventor(s) is/are the true & first inventor(s) for this Invention and declare that the applicant(s) herein is/are my/our assignee or legal representative.					
(a) Date: 20th Jan 2021 (b) Signature(s)  (c) Name(s) Dr. Vishal M. Balaramnavar					



Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery

Mayuri S. Prasad^a, Ritesh P. Bhole^b, Pramod B. Khedekar^{a,*}, Rupesh V. Chikhale^{c,*}

^a Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440033, MS, India

^b Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, Maharashtra, India

^c UCL School of Pharmacy, 29–39 Brunswick Square, London WC1N 1AX, United Kingdom

ARTICLE INFO

Keyword:

Tuberculosis
Enoyl acyl carrier protein reductase (InhA)
Multi-drug resistant TB
INH-NAD adduct
Kat G

ABSTRACT

Enoyl acyl carrier protein reductase (InhA) is a key enzyme involved in fatty acid synthesis mainly mycolic acid biosynthesis that is a part of NADH dependent acyl carrier protein reductase family. The aim of the present literature is to underline the different scaffolds or enzyme inhibitors that inhibit mycolic acid biosynthesis mainly cell wall synthesis by inhibiting enzyme InhA. Various scaffolds were identified based on the screening technologies like high throughput screening, encoded library technology, fragment-based screening. The compounds studied include indirect inhibitors (Isoniazid, Ethionamide, Prothionamide) and direct inhibitors (Triclosan/Diphenyl ethers, Pyrrolidine Carboxamides, Pyrroles, Acetamides, Thiadiazoles, Triazoles) with better efficacy against drug resistance. Out of the several scaffolds studied, pyrrolidine carboxamides were found to be the best molecules targeting InhA having good bioavailability properties and better MIC. This review provides with a detailed information, analysis, structure activity relationship and useful insight on various scaffolds as InhA inhibitors.

1. Introduction

1.1. Tuberculosis: history and current aspects

Tuberculosis is a contagious disease that continues to remain a major health problem and a major cause of mortality and morbidity in various developing countries. Hermann Heinrich Robert Koch discovered tuberculosis as an infectious disease and *Mycobacterium tuberculosis* (Mtb) as its causative microorganism which belongs to the family Mycobacteriaceae [1]. The discovery of Koch, his contribution to bacteriology and elucidations on the etiology of tuberculosis awarded him the Nobel prize for

Physiology in 1905 [2]. The invention of anti-TB drugs in the year 1950 made it possible for the treatment of tuberculosis and cases of tuberculosis started declining during the 1960s and 1970s and the disease was found to be controllable. During the 1980s, the cases of TB started rising again because of immune suppressive disorders like HIV. The other reason for the increase in cases of TB is drug resistant strains in bacteria of TB due to mutations. The cases of drug resistance are mainly led by a lack of patient compliance to the therapeutic regimen [2,3].

Recently, data including diagnosis, advances, prevalence and treatment of TB was published by the World Health Organization (WHO) from 205 countries consisting 99% of world population. In 2014, TB led

Abbreviations: ACN, Acetonitrile; AS, Arabian synthesis; AT, Arabinofuranosyl transferase; BACE1, β -site amyloid precursor protein cleaving enzyme 1; DCM, Dichloromethane; DIEA, N,N-diisopropylethylamine; DMF, Dimethyl formamide; DOTS, Directly observed therapy short course; DprE, Decaprenylphosphoryl-*o*-ribose-2'-epimerase; ETH, Ethionamide; Fab D, malonyl Co-A-ACP transacylase; Fab H, β -Ketoacyl ACP-synthase-III; FAS, Fatty acid synthase; FBDD, Fragment based drug discovery; Had ABC, β -Hydroxyacyl-ACP dehydratase; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluoro phosphate; HTS, High throughput screening; IC, Inhibitory concentration; INH, Isoniazid; InhA, Enoyl acyl carrier protein reductase; Kas AB, β -Ketoacyl-ACP synthase; Kat G, Catalase peroxidase; LSL, Lower substrate binding loop; MA, Mycolic acids; Mab A, β -Ketoacyl-ACP reductase; MDR-TB, Multi-drug resistance tuberculosis; MIC, Minimum inhibitory concentration; MSL, Middle substrate binding loop; NAD, Nicotinamide adenine dinucleotide; NOE, Nuclear overhauser enhancement; PG, Peptidoglycan; PIFA, Phenyl iodine (III) bis(trifluoroacetate); PTH, Prothionamide; RNTCP, Revised national tuberculosis control programme; RU, Resonance units; SBL, Substrate binding loop; SBP, Substrate binding pocket; SPR, Surface plasmon resonance; TARGET, Tuberculosis Animal Research and Gene Evaluation Taskforce; TB, Tuberculosis; TCN, Triclosan; TFA, Trifluoroacetic acid; USL, Upper substrate binding loop; Water-LOGSY, Water-ligand observed via gradient spectroscopy; WHO, World health organization; XDR-TB, Extensively drug resistance tuberculosis.

* Corresponding authors.


E-mail addresses: pbkhedekarudps@gmail.com (P.B. Khedekar), R.Chikhale@ucl.ac.uk (R.V. Chikhale).

<https://doi.org/10.1016/j.bioorg.2021.105242>

Received 22 May 2021; Received in revised form 16 July 2021; Accepted 2 August 2021

Available online 8 August 2021

0045-2068/© 2021 Published by Elsevier Inc.



Challenges in targeting mycobacterial ATP synthase: The known and beyond

Mangesh Mapari^a, Ritesh P. Bhole^b, Pramod B. Khedekar^a, Rupesh V. Chikhale^{c,*}

^a Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440033, MS, India

^b Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, Maharashtra 411018, India

^c UCL School of Pharmacy, 29–39 Brunswick Square, London WC1N 1AX, United Kingdom

ARTICLE INFO

Article history:

Received 11 July 2021

Revised 10 August 2021

Accepted 16 August 2021

Available online 21 August 2021

Keywords:

Mycobacterium tuberculosis

ATP synthase

Drug resistance

ATP synthase inhibitors

ABSTRACT

Adenosine Triphosphate synthase (ATPs) is an important enzyme for the synthesis of adenosine triphosphate (ATP). ATP is principal source of energy for growth and development of *mycobacteria*. ATPs is a validated drug target for discovery of new anti-TB drug against drug resistant bacterial strain. Since then, inhibitor with different type of chemical scaffolds have been reported for their activity against this enzyme. Formation of polar and non-polar interaction by ligand with this enzyme causes loss of catalytic activity which ultimately lead to death of *mycobacterium*. This review describes various ATPs inhibitors, their biological activity, and Structure Activity Relationship (SAR) reported in various literature up to date. We look beyond for the search of newer ATPs inhibitor or combination therapies to tackle drug resistant tuberculosis.

© 2021 Elsevier B.V. All rights reserved.

1. Introduction

Tuberculosis (TB) is a contagious disease caused by pathogenic bacteria *Mycobacterium tuberculosis* (*Mtb*). The emergence of drug resistance by mycobacterial strain is serious health issue worldwide [1]. The ordinary causes of resistance is genetic alteration and mutation *mycobacterium bacilli* [2,3].

According to WHO globally an estimated 10.0 million active TB cases in 2019, however, the number of TB cases has been slowly declining in recent years. The death rate in TB patients is estimated 1.2 million per year worldwide. Drug-resistant TB continues to be a public health threat worldwide. Multi drug resistant tuberculosis (MDR-TB) is defined as *Mtb* infection that shows resistance to isoniazid (INH) and Rifampicin (RMP). Three countries with the largest share of the global burden were India (27%), China (14%) and the Russian Federation (8%). In the year 2019, globally 3.3% of new TB cases and 17.7% of previously treated cases had MDR-TB. The highest proportions were in countries of the former Soviet Union [4]. The occurrence of drug resistance to *Mtb* is terrible condition in health care system and serious efforts are necessary to discover new drug molecules to act against *Mtb* by hitting at the novel targets [5].

Mycobacterial ATP Synthase is a novel molecular target for development of new anti-TB molecules against drug resistant TB

strains. The bacterial ATPs are also known as F_0F_1 -ATP synthases and they differ very much among the eukaryotes, plant and bacteria. The recent discovery and use of Bedaquiline, a diarylquinoline derivative as ATP Synthase inhibitor are a promising effort to extensive drug resistant (XDR) and MDR *Mtb* infections (Table 1). This also paves the way for medicinal chemists to discover new ATP synthase inhibitors which are more effective and potent against MDR and XDR *Mtb* strain.^{6,7}

2. *Mycobacterium tuberculosis*: drug target and inhibitors

Mycobacterium tuberculosis is the etiological agent of tuberculosis. It is spread when a person with active TB disease in their lung's coughs or sneezes and someone else inhales the expelled droplets, which contain the *mycobacteria*.

The current treatment protocol for TB consists of three lines of therapeutic regimen based on effectiveness of drug. Primary treatment starts with first line drugs like; Isoniazid [1], Rifampicin [2], Pyrazinamide [3], and Ethambutol [4] (Table 2). These drugs are provided at free of cost under various government schemes for the treatment of tuberculosis. Second line drugs for treatment of TB are; Streptomycin [5], Kanamycin [6], Amikacin [7], Capreomycin [8], Ofloxacin [9], Levofloxacin [10], Moxifloxacin [11], Ethionamide [12], Prothionamide [13], Cycloserine [14], Terizidone [15], And P-Aminosalicylic Acid [16] Amoxicillin [18]. In the case of MDR-TB, the drugs available for treatment are very limited and consist of Clofazimine [17], a combination of Amoxicillin [18] and Clavulanic

* Corresponding author.

E-mail address: R.Chikhale@ucl.ac.uk (R.V. Chikhale).



Research article

Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents



Ritesh P. Bhole^{a,*}, Rupesh V. Chikhale^{b,c}, Ravindra D. Wavhale^a, Fatmah Ali Asmary^d, Tahani Mazyad Almutairi^d, Hassna Mohammed Alhajri^d, Chandrakant G. Bonde^e

^a Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, Maharashtra, India

^b Division of Pharmacy and Optometry, University of Manchester, Manchester, UK

^c School of Pharmacy, University of East Anglia, Norwich, UK

^d Department of Chemistry, P.O. Box 2455, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia

^e School of Pharmacy & Technology Management, SVKM's NarseeMonjee Institute of Management & Studies (NMIMS), Mukesh Patel Technology Park, Shirpur, Dhule, 425405, Maharashtra, India

ARTICLE INFO

Keywords:

Hybrid molecules
Prostate cancer
Imidazolidinone derivatives
Molecular docking
Molecular dynamics simulations
Binding energy calculations

ABSTRACT

The androgen receptor inhibitor, Enzalutamide, proved effective against castration resistance prostate cancer, has demonstrated clinical benefits and increased survival rate in men. However, AR mutation (F876L) converts Enzalutamide from antagonist to agonist indicating a rapid evolution of resistance. Hence, our goal is to overcome this resistance mechanism by designing and developing novel Enzalutamide analogues. We designed a dataset of Enzalutamide derivatives using Enzalutamide's shape and electrostatic features to match with pharmacophoric features essential for tight binding with the androgen receptor. Based on this design strategy ten novel derivatives were selected including 5,5-dimethyl-3-(6-substituted benzo[d]thia/oxazol-2-yl)-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one (6a-j) for synthesis. All the compounds were evaluated *in-vitro* on prostate cancer cell lines DU-145, LNCaP and PC3. Interestingly, two compounds 3-(6-hydroxybenzo[d]thiazol-2-yl)-5,5-dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one (6c, IC₅₀ – 18.26 to 20.31 μM) and 3-(6-hydroxybenzo[d]oxazol-2-yl)-5,5-dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one (6h, IC₅₀ – 18.26 to 20.31 μM) were successful with promising *in-vitro* antiproliferative activity against prostate cancer cell lines. The binding mechanism of potential androgen receptor inhibitors was further studied by molecular docking, molecular dynamics simulations and MM-GBSA binding free energy calculations and found in agreement with the *in vitro* studies. It provided strong theoretical support to our hypothesis.

1. Introduction

Prostate cancer is the cancer of prostate gland in the male reproductive system, which is the second most frequent cancer in men and fifth amongst all cancer mortality. According to the World Health Organization report, in 2018, 1.28 million new prostate cancer cases were found of 18.1 million cancer cases, worldwide [1]. Prostate cancer is generally observed in older age patients with asymptomatic during the early stage. Later, most common complaints are difficulty in urination, blood in urine and pain in pelvis or back. Treatment strategies of prostate cancer are based on lowering the male sex hormone levels called testosterone, as it plays a central role in cancer growth. Testosterone level can be reduced either by surgical castration [2] (removal of testicles) or by testosterone

lowering agents (Androgen deprivation therapy or ADT). ADT includes steroidal or nonsteroidal drugs like Luteinizing Hormone, Releasing hormone agonist and antagonist that reduces blood testosterone levels or Androgen receptor inhibitors, which block testosterone's entry in the cell (cancer cell). Competitive Inhibition of androgen binding to the androgen receptors (AR) using AR antagonists like Flutamide, Nilutamide, and Bicalutamide (First generation AR antagonists) reduces androgen concentration inside the cell [3]. However, development of resistance due to AR mutations, Synthesis of androgen by prostate cancer cells, overexpression of AR, and AR antagonists' turning to agonists makes these conventional AR antagonists ineffective in treating castration-resistant prostate cancer (CRPC) [4].

* Corresponding author.

E-mail address: ritesh.bhole@dypvp.edu.in (R.P. Bhole).

<https://doi.org/10.1016/j.heliyon.2021.e06227>

Received 20 September 2020; Received in revised form 13 January 2021; Accepted 4 February 2021

2405-8440/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Review article

Nanocarriers based oral lymphatic drug targeting: Strategic bioavailability enhancement approaches

Priyanka Pandya^a, Prabhanjan Giram^b, Ritesh P. Bhole^c, Hsin-I Chang^d, Sushil Y. Raut^{b,*}^a Department of Pharmaceutics, Shree Dhanvantary Pharmacy College, Kim, Surat, 394110, Gujarat State, India^b Department of Pharmaceutics, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, Maharashtra, India^c Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, Maharashtra, India^d Department of Biochemical Sciences and Technology, National Chiayi University, 300 Syuefu Road, Chiayi City, 60004, Taiwan

ARTICLE INFO

Keywords:

Lymphatic drug delivery
Peyer's patches
Chylomicrons
Nanocarriers

ABSTRACT

In dosage form design, drug delivery technology facing a major problem due to degradation of the drug through the first-pass metabolism upon oral delivery. We can overcome this bioavailability-related problem by adopting the intestinal lymphatic pathway for drug delivery. Nanocarriers like lipid nanoparticles, polymeric nanoparticles, liposomes, emulsions, etc. can be used to enhance the lymphatic uptake of drugs. In the lymphatic pathway absorption of drugs takes place by endocytosis via Peyer's patches and the chylomicron uptake. Peyer's patches exhibit M-cells which represent many receptors like mannose receptors, folate receptors, claudins, integrins, transferrin receptors, biotin receptors etc. Targeting these receptors through nanocarriers can improve the lymphatic absorption of drugs and thus improve bioavailability. Targeting drugs through the lymphatic system can treat many diseases including cancer, AIDS, tuberculosis, lymphodema, diabetes, schizophrenia, etc. Thus, by using lymphatic drug delivery systems we can improve the treatment efficacy, survival, and life expectancy of the patient. In this article, we discussed various strategies to enhance drug bioavailability through lymphatic targeting.

1. Introduction

The lymphatic system is one of the circulatory systems like the blood circulatory system. It is also known as a drainage system that presents throughout the body [1]. Lymphatic targeting can be used to address a variety of issues, including the first-pass metabolism from oral administration. Since lymph nodes play a large role in tumor metastasis, lymphatic targeting has been preferred in the treatment of cancer, AIDS, and a variety of other diseases [2]. It consists of a complicated network of tubes or channel which carries fluid known as lymph [1]. The lymphatic system consists of two main parts: (1) Lymph & (2) Lymphatic pathway. The lymphatic pathway includes capillary lymph, lymph vessel, lymph duct, and lymph organs such as lymph nodes, spleen, and thymus. It is the undirected pathway. The main function of the lymphatic system is to maintain the balance of the body's water like a blood vessel. It is very useful in the oral absorption of lipids, fats, and lipophilic drugs [3]. The lymph vessels are usually large in size than the blood vessels, the pressure in the vessels is smaller and the lymph circulation is slower. Capillaries in the lymphatic system are made up of

endothelial cells and collagenous fibers. There is no tight junction in the lymphatic walls like blood vessels that has large gaps between endothelial cells. Lymphatic capillary walls allowed small particles to enter the system [4]. The Lymph system also contributes to a number of illnesses, including lymphedema, metastasis of cancer, and multiple inflammatory disorders. Nowadays's lymphatic system is more preferable for drug delivery than the portal system, because drug agents, which could benefit from lymphatic concentration, are like anticancer chemotherapeutics and vaccines, might be designed for preferential use in the lymphatic system with reduced systemic distribution to improve efficacy. A lymphatic system has unique physiological functions in lipid absorption and particulate absorption that might be applied as an alternative route for pharmaceutical delivery to improve their bioavailability and effectiveness [5]. Fig. 1 showed detailed Uptake of nanoparticles across cell membrane Endocytosis, Phagocytosis, Pinocytosis, and receptor-mediated endocytosis.

The oral route is most acceptable and widely used for the administration of a variety of drugs. There are many advantages of the oral route over other routes. It is safe and convenient due to pain-free and self-

* Corresponding author.

E-mail address: sushilraut01@gmail.com (S.Y. Raut).<https://doi.org/10.1016/j.jddst.2021.102585>

Received 14 January 2021; Received in revised form 14 May 2021; Accepted 15 May 2021

Available online 18 May 2021

1773-2247/© 2021 Elsevier B.V. All rights reserved.

Alpha-Synuclein: Biomarker for Parkinson's Disease, It's Estimation Methods, and Targeted Medicinal Therapies



Shivani V. Dhokne, Vaishali R. Undale, **Dinesh Chandra Agrawal**, and Sharad D. Pawar

Contents

1	Introduction	229
2	Structure and Functions of α -Synuclein	230
3	Pathways Implicated in α -Synuclein Neurotoxicity	234
4	Alpha-Synuclein as a Diagnostic Biomarker in Parkinson's Disease	235
4.1	Measurement of α -Synuclein in Peripheral Tissues and Body Fluids	236
5	Methods for Estimation of α -Synuclein	236
5.1	Measurement of α -Synuclein in Human Cerebrospinal Fluid	236
5.1.1	Assay Procedure	237
5.1.2	Dot Blot	237
5.2	Measurement of α -Synuclein in Human Plasma	238
5.2.1	Preparation Method	238
5.2.2	Detection Method	238
5.3	Measurement of α -Synuclein in Saliva	238
5.3.1	Saliva Sample Collection and Preparation	239
5.3.2	Western Blot	239
5.3.3	Luminex Assay	239
5.3.4	Electron Microscopy	239
5.4	Immunohistochemistry	240
5.5	Thioflavin T Fluorescence Assay	240
5.5.1	Purification of Acetylated α -Synuclein	240
5.5.2	Sample Preparation Method	241

S. V. Dhokne

Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, India

V. R. Undale

Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, Maharashtra, India

D. C. Agrawal (✉)

Department of Applied Chemistry, Chaoyang University of Technology, Taichung, Taiwan

e-mail: dcagrawal@gm.cyut.edu.tw

S. D. Pawar (✉)

Regional Ayurveda Institute for Fundamental Research, Pune, Maharashtra, India

e-mail: rophraifr.pu-ayush@gov.in

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18**

Notable achievements for Research and Innovations



Certificate Of Achievement

**ZEE MEDIA hereby awards this Certificate of
Achievement to**

Dr D Y Patil Institute of Pharmaceutical

Outstanding Engineering Institute for Research and Innovation

**For their outstanding contribution towards
education and shaping up the future of students**

Date – June 25, 2021

Mr. Abhishek Nigam

(Chief Operating Officer)

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Career Plan Survey Sheet**

Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune.

CAREER SURVEY 2020-2021

* Required

1. Career plan Survey for Final year *

Mark only one oval.

☐ B.Pharm

☐ M.Pharm

2. Name of Student *

3. Higher Education *

Check all that apply.

☐ M.Pharm

☐ MBA

☐ MS

☐ PhD

☐ Other

4. Carrer Option *

Check all that apply.

☐ Marketing

☐ PV

☐ Production

☐ QA

☐ F&D

☐ Entrepreneur

☐ Other

5. Ready to relocate *

Mark only one oval.

☐ Yes

☐ No

6. Email id *

7. Mobile No. *

8. Driving Licence No.

9. Pan Card No.

10. Language Known *

Check all that apply.

☐ English

☐ Hindi

☐ Marathi

☐ Other

11. Goal to Achieve *

Mark only one oval.

- ☐ Carrer Goal
- ☐ Personal Goal
- ☐ Other

12. Computer Proficiency *

13. Instrument/Equipment Expertise *

Check all that apply.

- ☐ UV
- ☐ HPTLC
- ☐ NMR
- ☐ IR
- ☐ XRD
- ☐ LCMS
- ☐ Other

14. Professional Courses completed *

Check all that apply.

- ☐ RA
- ☐ PV
- ☐ CRA
- ☐ QBD
- ☐ Biostat
- ☐ CGMP
- ☐ CGLP
- ☐ Pharma validation
- ☐ Other

15. Soft skill training/ Workshop attended *

Check all that apply.

- ☐ Personality Development
- ☐ Corporate Training
- ☐ Resume Writing
- ☐ Other

16. Extra Curricular Activity Achievement

17. Prizes won if any

18. Add-on courses required from the institute

19. Personal skills if any

This content is neither created nor endorsed by Google.

Google Forms


Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Customized training programs**

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune – 411018


Date: 06/04/2021

Type of Program	Pre-placement
Speaker/Trainer	Mr. Punit Ganatra
Topic	Orientation on Job profile & Junior Scientific and Medical Writer and interview process
Date	06 April 2021
Brief Report	An online pre-placement training session on "Orientation on Job profile as Junior Scientific and Medical Writer and interview process" of Springer Nature was organised by Placement Cell, DPU Pharmacy. Mr. Punit Ganatra, Human Resource, Springer Nature was the speaker of the session. The students gained knowledge on various career avenues with springer nature as a "Junior Scientific and Medical Writer and interview process". The detail job profile explained by speaker and also career scope was discussed. He oriented about interview process with students and motivated them to complete the process successfully. The session was interactive one, M.Pharm and B.Pharm students were actively participated in the session.
PO's attained	A, B, C, E, F, H, K
Number of Beneficiaries	




Dr. Tanaji Nandgude
(In-charge)





Dr. S. S. Chitlange
(Principal)

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical science and Research
Pimpri, Pune -411018.**



Orientation on Job profile "Junior Scientific and Medical Writer and interview process



Interactions with students

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune – 411018

Date: 25/06/2020

Type of Program	Webinar (Zoom platform)
Resource Person	Dr. Zoya Waseem S, Director, Zee Edutech Learning, Training and Organisation Development, Pune.
Topic	" Career in Pharmacy: Skill Requirement "
Date	23rd June 2020
Brief Report	A webinar on "Career in Pharmacy: Skill Requirement " 23rd June 2020, as a part of a webinar series on career in Pharmacy. The guest speaker for the session was Dr. Zoya Waseem S. The session was co-ordinated by Training and Placement Cell with the objective to familiarise students about various career opportunities and to create impact on importance of various skill requirements for career development. The expert delivered the inspirational and informative talk with details of application of skills to various domains. The session witnessed the D.Pharm, B. Pharm, Pharm. D and M.pharm students, which helped them to understand various types of skill requirements for pharmacy careers.
PO's attained	A, C, D,E,F,H,K


Dr. T. D. Nandgude
(In-Charge)


Dr. S. S. Chitlange
(Principal)



Dr. Zoya Waseem S, Director , Zee Edutech Learning , Training and Organization Development , Pune interacting with students.

Zoom Meeting | You are viewing Dr. Zoya W. S.'s screen | View Options

Recording... | Speaker View

Career/Opportunities after D.Pharm./ B. Pharm./M.Pharm

PHARMA TREE

Production & Manufacturing
Responsible for the production of pharmaceutical products.

Regulatory Affairs
Responsible for the regulatory aspects of pharmaceutical products.

Quality Assurance
Responsible for the quality of pharmaceutical products.

Marketing
Responsible for the marketing of pharmaceutical products.

Regulatory Bodies
Responsible for the regulatory aspects of pharmaceutical products.

Chemist Shop
Responsible for the sale of pharmaceutical products.

Entrepreneurship
Responsible for the business aspects of pharmaceutical products.

Higher Studies
Responsible for the higher studies in pharmaceuticals.

Other Opportunities
Responsible for the other opportunities in pharmaceuticals.

Shikha Desai	Ms. Anagha Go...	Dr. Zoya W. S.	Galary J7 Nat
Dr. Tanaji Nand...	DPU	Akib Korbu	Mayuri Nazirkar
Rushikesh pato...	Vaishnavi	Jayashree Chau...	Sakshi
Diksha Tapsale	n	QCOM-BTD	Mamta rajawat
Redmi 2	fea22c26	Karan Lokhande	Sampada
Niteen jadhav	Ashya Mulani	JADHAV NAMR...	Sonija Bankh...

Unmute | Start Video | Security | Participants | Chat | Share Screen | Pause/Stop Recording | Reactions | Leave

**Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune – 411018**


Date: 28/12/2021

Type of Program	Session
Speaker/Trainer	Dr. Kanav Khara, Associate Professor, Lovely Professional University, Punjab
Topic	Scope of Biomedical Ethics and Clinical Research: Current Trends and Future Perspectives
Date	27 December 2021
Brief Report	The Training and Skill Development Cell of Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research conducted an interactive session on Scope of Biomedical Ethics and Clinical Research: Current Trends and Future Perspectives on 27th December 2021. The speaker for the session was Dr. Kanav Khara. Dr. Kanav Khara presented the session in a very informative manner. He started with the history of clinical trials and gave the timeline for the development of various rules related to the conduct of trials. He emphasized on the accelerated clinical trials and research ethics. He very well explained the subjects related to documentation and patient safety. He mentioned the key points related to good clinical practice and its relevance to Pharmacy Practice students. He gave an overview about clinical trial website and database. Dr Kanav Khara highlighted the roles and responsibilities of Pharm D students. He also emphasised on the scope of Pharmacy Practice in the current scenario. The session involved active participation.
PO's attained	A, D, F, G, I, K


Dr. Sneha Chandani
(In-charge)




Dr. S. S. Chitlange
(Principal)




Dr. Dr. Kanav Khera guiding students regarding Scope of Biomedical Ethics and Clinical Research: Current Trends and Future Perspectives

**Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune – 411018**



Date: 25/10/2021

Type of Program	Online (Zoom)
Speaker/Trainer	Dr. Dharmesh Mehta, Trainer, Pharmaelite
Topic	Strategy For GPAT and NIPER Preparation
Date	21 October 2021
Brief Report	The Training and Skill Development Cell of Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research conducted an interactive session on Strategy For GPAT and NIPER Preparation on 21st October 2021, as a part of Celebration of "National Pharmacovigilance Week 2021". The speaker for the session was Dr. Dharmesh Mehta. The session was indeed essential. Dr. Dharmesh Mehta presented the session in a very informative manner. He described in brief about GPAT and NIPER preparation. He also emphasized about the key points related to the GPAT examination and strategies for study. He gives over view of subject that important for GPAT examination. He explained the important books study material, sample MCQ important for students. The session involved active participation.
PO's attained	A, C, F, G, I, J, K


Dr. Sneha Chandani •
(In-charge)




Dr. S. S. Chitlange
(Principal)



Dr. Dharmesh Mehta explaining about Strategy For GPAT and NIPER Prepration

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **GPAT guidance sessions summary**

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research,
Pimpri, Pune-411018

Schedule for GPAT preparative Classes 2020-21

Sr. No.	Saturdays	Time	Name of the student	Topic to be discussed	Teacher Coordinator
1.	11/07/2020	11:00am-1:00pm	Ms. Diksha Vijay Tapsale	Novel drug delivery system	Dr. Tanaji Nandgude
2.	18/07/2020	11:00am-1:00pm	Ms. Jagruti Shyam Shimpi	Anti-tubercular drugs	Ms. Shivani Sainani
3.		1:30 pm - 3:30pm	Mr. Sakib Habib Tamboli	Dispersion systems	Dr. Sanjivani Deshkar
4.	25/07/2020	11:00am-1:00pm	Ms. Bhagyashree Ganesh Waykar	Dosage form necessity and additives	Dr. Jayashri Mahore
5.		1:30 pm - 3:30pm	Ms. Shweta Nitinkumar Jadhav	Chemotherapeutics agents	Dr. Lata Kothapalli
6.	04/08/2020		Ms. Roshani Sanjay Paradhi	Pharmacognostic study of lipids and resins	Dr. Maruti Shelar/Ms. Juilee Jagtap
7.	11/08/2020		Mr. Dhyneshwar Khodse	Basics of Pharmacognosy	Dr. Maruti Shelar
8.	18/08/2020		Ms. Snehal Dnyandeav Kapse	Flame photometry and atomic absorption spectroscopy	Mrs. Rachana Bhimanwar
9.	20/08/2020		Ms. Priya Dilip Garad	Tablets	Dr. Prabhanjan Giram
10.	25/08/2020		Ms. Harshada Ramesh Ghadage	HP TLC and NMR	Dr. Asha Thomas
11.	27/08/2020	4:00pm-6:00pm	Ms. Prajakta Ashok Kamble	Anti-cholinergic agents	Dr. Karan Rathi
12.	03/09/2020		Ms. Roshani Rajendra Pagar	Capsules	Ms. Shubhangi Shinde / Dr. Karan Rathi



				Dr. P. S. Giram
13.	08/09/2020	Ms. Prachi Rajesh Dugam	CVS	Dr. Shivani Desai
14.	10/09/2020	Ms. Tamanna Vajir Tamboli	Kinetics, Viscosity and rheology	Mr. Rakesh Mishra
15.	22/09/2020	Mr. Rahul Anna Thore	Packaging material	Dr. Harshad Kapre/ Mr. Rakesh Mishra
16.	24/09/2020	Ms. Vijaya Ramdas Mandale	Mass Spectroscopy	Dr. Asha Thomas/ Dr. Sejal Gandhi
17.	29/09/2020	Ms. Kalyani Gautam Ovhal	Cosmeceuticals	Mr. Devendra Visokar
18.	01/10/2020	Mr. Sanket Dattu Thorat	Quality control and standardisation of herbal drugs	Dr. Santosh Bhujbal
19.	06/10/2020	Mr. Shubham Rajendra Musale	Parenterals	Dr. Harshad Kapre
20.	08/10/2020	Mr. Pranav Ramchandra Modak	Antibiotics	Dr. Ravindra Wavhale
21.	13/10/2020	Ms. Shweta Shripad Kulkarni	Pharmaceutical aerosols	Dr. Jayashri Mahore/Ms. Sonali Labhade
22.	15/10/2020	Mr. Anil Kailash Saini	Carbohydrates and biological oxidations and reductions. Precipitation Titration	Dr. Scjal Gandhi
23.	20/10/2020	Mr. Rohit Gurappa Kumbhar	Anti-epileptic drugs	Dr. Dhiraj Bhombhe
24.	22/10/2020	Ms. Mayuri Avinash Kale	Sulphonamides, Thyroid and antithyroid agents (Medichem)	Dr. Ritesh Bhole
25.	27/10/2020	Mr. Prafulla Yuvraj Dhakare	Chemical tests	Ms. Angha Godse

4:00pm-
6:00pm



			(Pharmacognosy)	
26.	29/10/2020	Mr. Mahadevan Raju Swamy	Heterocyclic chemistry	Mr. Yogesh Zambare
27.	24/11/2020	Ms. Kaveri Aher	Stereochemistry and Name reaction	Me. Subhash Chate
28.	26/11/2020	Ms. Roshani Rajendra Pagar Ms. Diksha Vijay Tapsale	Immunology, Vaccines and Sera, Bacteria, Staining, Virus	Ms. Shubhangi Shekade and Dr. Jayashri Mahore
29.	1/12/2020	Ms. Ankita Kotikwar	Colloids	Dr. Sanjeevani Deshkar
30.	3/12/2020	Mr. Saras Hemant Tiwari	Basics and pharmacology of Autonomic nervous system.	Dr. Vaishali Undale

[Signature]
Dr. J. G. Mahore/Dr. S. P. Gandhi
(Academic In-Charge)

[Signature]
Dr. S. S. Bhujbal
(Academic Co-ordinator)

[Signature]
Dr. S. S. Chitlange
(Principal)



Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research,
Pimpri, Pune- 411018

Syllabus covered in GPAT preparative classes 2020-21

Sr.No.	Date	Topic covered	Name of student	Teacher Coordinator	Signature
1.	11/7/2020	Novel Drug Delivery Systems	Ms. Diksha Tapasabe	T.D. Nandgaute	
2.	11/7/2020	Antitubercular drugs.	Ms. Jagruti Shimpi	Ms. Shivani Jainani	
3.	18/7/2020	Dispersion Systems	Mr. Saheb Tambdi	Dr. S.S. Deshpande	
4.	25/7/2020	Chemotherapeutic agents	Mr. Shweta Jadhav	Dr. L.P. Kowgall	
5.	05/8/2020	Dosage form nomenclature & additives.	Ms. Shoaqastree Wajnar	Dr. Jayshree Mahore	
6.	04/08/20	Pharmacognostic Studies	Ms. Rashmi Parthvi	Dr. M.K. Sholekar	
7.	11/08/20	Basic of Pharmacology	Mr. Dnyaneshwar Khobare	Dr. M.K. Sholekar	
8.	13/8/2020	Flame photometry	Sneha Kapase	Ms. R.S. Bhimanwar	
9.	20/8/2020	Tablets.	Ms. Priya Garad.	Dr. P.S. Giram.	
10.	25/8/2020	HPTLC & NMR	Ms. Harshada G.	Dr. A.B. Thomas	
11.	24/8/2020	Anti-cholinergic agents	Ms. Pranjyoti Kamble	Dr. K.M. Rath	
12.	31/8/2020	Capsule.	Prajyoti Rashmi Pagar.	Ms. S.V. Shetkar	
13.	08/09/20	CNS	Ms. Pradi Dugam	Dr. Shivani Desai	
14.	10/09/20	Kinetics, viscosity & rheology	Ms. Tamanna Tamboli	Mr. Rakesh Chikara	
15.	22/09/20	Packaging material	Mr. Rahul A Thore	Dr. H.S. Kapane	


16.	24/09/2020	Mass	Dr. A. B. Thomas	Dr. A. B. Thomas	Dr. A. B. Thomas	Baudhi
17.	29/09/2020	cosmeceuticals	Vijaya Maudale	Dr. S. P. Gaudhi	Dr. S. P. Gaudhi	Baudhi
18.	31/10/2020	Quantitative analysis of standards of herbs	Ms. Kalyani Oshale	Mr. D. Visokar	Mr. D. Visokar	Baudhi
19.	6/10/2020	Parenterals	Ms. Sangeeta Thorat	Dr. S. S. Shinde	Dr. S. S. Shinde	Baudhi
20.	8/10/2020	Antibiotics	Mr. Shubham Musale	Dr. H. S. K. K. K. K.	Dr. H. S. K. K. K. K.	Baudhi
21.	13/10/2020	pharmaceutical Aerosols	Dr. Ravindra P. Wamale	Dr. R. D. Wamale	Dr. R. D. Wamale	Baudhi
22.	15/10/2020	Carbohydrate ppt. filtration	Ms. Shweta Kulkarni	Dr. J. G. Mahore	Dr. J. G. Mahore	Baudhi
23.	20/10/2020	Anti-epileptic Drugs.	Mr. Rohit Kumbhar	Dr. Dhirej B. B. B.	Dr. Dhirej B. B. B.	Baudhi
24.	22/10/2020	Sulphonamides ppt	Ms. Mayuri Icar	Dr. R. P. B. B.	Dr. R. P. B. B.	Baudhi
25.	27/10/2020	Chemical tests	Mr. Pratul Phatak	Miss. A. K. Godse	Miss. A. K. Godse	Baudhi
26.	29/10/2020	Heterocyclic Chemistry	Mr. S. S. S. S.	Dr. R. B. Zambare	Dr. R. B. Zambare	Baudhi
27.	24/11/2020	Stereochem & Naming Reactions	Ms. Kaveri Ahir	Mr. S. G. Chate	Mr. S. G. Chate	Baudhi
28.	28/11/2020	Pharmaceutical, Vaccine	Dr. P. P. P. P.	Ms. S. V. Gekade	Ms. S. V. Gekade	Baudhi
29.	1/12/2020	Colloids	Ms. Ankita K. K. K.	Dr. S. S. S. S.	Dr. S. S. S. S.	Baudhi
30.	3/12/2020	Basics & Pharmacology of ANS	Mr. Satish Tiwari	Dr. V. R. Undale	Dr. V. R. Undale	Baudhi

Baudhi
Dr. S. P. Gandhi
(Academic-In-charge)


Dr. S. S. Bhujbal
(Academic Coordinator)



Vishwange
Dr. S. S. Chitlange
(Principal)



Dr. P. S. Giram during his session in GPAT preparative classes



Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Mock interview session**

**Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune- 411018**

Date: 30/03/2021

NOTICE

All the Final Year B.Pharm students and S.Y. M.Pharm students are hereby informed that a Pre-Placement sessions are arranged on **"Pharmacovigilance: Current trends and future scope"** by Mr. Nitin Patil, Training Lead - PV & **"Interview Skills & Preparation"** by Ms. Shweta Joshi, Soft Skill Trainer on Wednesday, 31st March 2021 at 01.00 pm to 03:30 pm.

The sessions are planned on the online platform (Zoom), login details will be provided & attendance for the same is mandatory.


Dr. T. D. Nandgude
(Incharge)




Dr. S. S. Chitlange
(Principal)

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune - 411018

Date: 31/03/2021

Type of Program	Guidance Session
Speaker/Trainer	Mr. Nitin Patil
Topic	Pharmacovigilance: Current trends and future scope
Date	31 March 2021
Brief Report	An online pre-placement guidance session on "Pharmacovigilance: Current trends and future scope" by Mr. Nitin Patil, Training Lead - PV, Cognizant was organised by Placement Cell, DPU Pharmacy. The students gained knowledge on various aspects of Pharmacovigilance, with various current trends and future aspects. Mr. Nitin guided students about career opportunities and also oriented students on PV interviews. He has also conducted online quiz competition on PV for B.Pharm and M.Pharm students.
PO's attained	A, B, G, H, K
Number of Beneficiaries	35


Dr. Tanaji Nandgude
(In-charge)




Dr. S. S. Chitlange
(Principal)

GUIDANCE SESSION

PHARMACOVIGILANCE CURRENT TRENDS AND FUTURE SCOPE

Final Year B.Pharm and
S.Y. M.Pharm students



MR. NITIN PATIL
*Training Lead
PV, Cognizant*



ORGANIZED BY
PLACEMENT CELL

**Dr. D. Y. PATIL INSTITUTE OF
PHARMACEUTICAL SCIENCES
AND RESEARCH**

Sant Tukaram Nagar, Pimpri
Pune - 411 018 (MH), INDIA




**31ST MARCH, 2021
01.00 PM ONWARDS**

ZOOM DETAILS WILL BE PROVIDED

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical science and Research
Pimpri, Pune -411018.**

Placement Cell

"Pharmacovigilance: Current trends and future scope"





Certificate

OF APPRECIATION



This is to certify that **Mr. Nitin Patil** has contributed as Resource Person in the Guidance Session on **"Pharmacovigilance - Current Trends and Future Scope"** organized by Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune on 31st March 2021. We thank him for sparing his valuable time to enlighten the students. His expert opinion in this guidance session is highly appreciated.

Dr. Tanaji Nandgude
Placement Officer


Dr. Sohan Chitlange
Principal

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune – 411018

Date: 31/03/2021

Type of Program	Guidance Session
Speaker/Trainer	Ms. Shweta Joshi
Topic	Interview Skills & Preparation
Date	31 March 2021
Brief Report	An online pre-placement guidance session on "Interview Skills & Preparation" by Ms. Shweta Joshi, Soft skill Trainer was organised by Placement Cell, DPU Pharmacy. Ms. Shweta guided students on various aspects like CV preparation, interview skills, and preparation of interviews with discussion on critical stages of interviews. Also, speaker interacted with students to solve queries raised by them on different aspects of PV or interview skill. Ms. Shweta also taken some mock interviews, evaluated interviews and guided all students for improvement.
PO's attained	A, B, C, E, F, H, K
Number of Beneficiaries	52


Dr. Tanaji Nandgude
(In-charge)




Dr. S. S. Chitlange
(Principal)

TRAINING SESSION

INTERVIEW SKILLS AND PREPARATION

Final Year B.Pharm and
S.Y. M.Pharm students



MS. SHWETA JOSHI
Soft Skill Trainer



ORGANIZED BY
PLACEMENT CELL

**Dr. D. Y. PATIL INSTITUTE OF
PHARMACEUTICAL SCIENCES
AND RESEARCH**

Sant Tukaram Nagar, Pimpri
Pune - 411 018 (MH), INDIA


31 MARCH, 2021
02.00 PM ONWARDS

ZOOM DETAILS WILL BE PROVIDED

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical science and Research
Pimpri, Pune -411018.**

Placement Cell

Title: "Interview Skills & Preparation"





Certificate

OF APPRECIATION



This is to certify that **Ms. Shweta Joshi** has contributed as Resource Person in the Training Session on **"Interview Skills and Preparation"** organized by Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune on 31st March 2021. We thank her for sparing her valuable time to enlighten the students. Her expert opinion in this training session is highly appreciated.

A handwritten signature in blue ink, appearing to read "Tanaji Nandgude".

Dr. Tanaji Nandgude
Placement Officer

A handwritten signature in blue ink, appearing to read "Sohan Chitlange".

Dr. Sohan Chitlange
Principal


**Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research,
Pimpri, Pune – 411018**

Date: 21/01/2021

Type of Program	Pre-placement
Speaker/Trainer	Dr. T D Nandgude & Placement Team
Topic	Orientation on Campus Drive and Mock Interviews for Production at Sandoz, Mumbai.
Date	21 January 2021
Brief Report	“Virtual orientation on Campus Drive and Mock Interviews for Production at Sandoz, (Novartis) Mumbai” was conducted by Placement Cell, with the objective to prepare students for Interview sessions and also to make them familiar with common interview questions asked during the HR round. The students of B.Pharm and M.Pharm final year (2019 and 2020 batch) actively participated in this program. The students were informed about the interview process, job responsibilities and various perks given by the company at the fresher level.
PO's attained	A, B, C, E, F H, K
Number of Beneficiaries	17


Dr. Tanaji Nandgude
(In-charge)





Dr. S. S. Chitlange
(Principal)

**Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical science and Research
Pimpri, Pune -411018.**

Placement Cell

“Orientation on Campus Drive and Mock Interviews for Production at Sandoz, Mumbai”



Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Training sessions summary**

Dr. D. Y. Patil Unitech Society's
Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research,
Pimpri, Pune-411018.

SUMMARY OF CUSTOMIZED TRAINING ACTIVITIES

Sr. No	Activity	Date
1.	Scope in Clinical Research and other domains, Mr. Vishal Chaudhari, Head of Operation, Clini India	08/06/2020
2.	Career counselling to Final Year B.Pharm students by Training and Placement Cell	09/06/ 2020
3.	Career in Pharmacy: Skill Requirement, Dr. Zoya Waseem S. , Zee Edutech	23/06/2020
4.	Career in Pharmacy: Indian Pharmaceutical Sector and Government Job, Mr. Mayur Parmar, Deputy Collector, Govt of Gujarat, Ex-Drug Inspector, India	29/06/2020
5.	Career in Pharmacy: Competitive Exams, Prof. Buge Pravin V., Career Counsellor, The Unique Academy, Pune	04/07/ 2020
6.	Mock interviews and orientation by T & P Cell for campus placement opportunities at Tata Consultancy services	27/07/2020
7.	Bottlenecks of Pharmacovigilance, Mr. Piyush Sanghai, Cognizant, Mumbai	04/08/ 2020
8.	Orientation session about career in research by Mr. Anshu Mukherjee, Head- HR & Admin, Sava Healthcare Ltd	21/08/2020
9.	Strategies for GPAT-NIPER, Dr Sachin Kushare, Infinity Education, Nashik & Dr Santosh Chhajed, Infinity Education, Nashik	19/9/2020
10.	Overseas Education, Mr Dnyaneshwar Nade, Founder and Director, PD Overseas Education Consultants, Pune	20/10/2020
11.	Opportunities in Pharma Industry and Guidance on Interview Skills, Mr Rahul Wathore, RBM, Leadership Trainer and Lifestyle Coach	9/11/2020
12.	Mock Interviews of B. Pharm students for placement opportunities at Gennova Biopharmaceuticals Ltd.	08/12/2020
13.	Establishment of Janaushadhi Kendra, Mr. Shreepal Suresh Kumar Samdariya, Deputy manager, Maharashtra and Goa, Bureau of Pharma PSU of India.(BPPI), Pradhan Mantri Bhartiya Janaushadhi Pariyojna	10/12/2020
14.	Global Study Opportunities in Pharmaceutical Sciences, Ms. Reshmy Vijay, Director, Education Matters	10/12/2020
15.	How to create an impressive profile? (CV+LinkedIn), Mr. Cherag Bachhawat, CEO, cvDragon, Kolkata, India	11/01/2021
16.	Training of Instruments of all departments	21/01/2021- 23/01/2021



17.	Interpersonal skills and Goal setting, Dr. Sonali Saha, Professor, DYP B School, Tathwade, Pune	04/02/2021
18.	Opportunities of Pharm D Course on Global Platform, Dr. Kavya Shaj, Toxicologist, Kimberly-Clark, Mumbai	04/02/2021
19.	Orientation session on Placement activities and Career Opportunities for D.Pharm	12/02/2021
20.	Clinical Research and Data Analytics	22/02/2021-25/02/2021
21.	Aptitude and Training Workshop, Mr. Pavan Nerniya, Aptitude Trainer, Soft skills trainer, Friends Union for Energising Lives	01/03/2021-04/03/2021
22.	How to ace your Summer Internship" an Internshala Career Talk 2021	09-03-2021
23.	An online pre-placement guidance session on "Pharmacovigilance: Current trends and future scope" by Mr. Nitin Patil, Training Lead – PV, Cognizant	31-03-2021
24.	An online pre-placement guidance session on "Interview Skills & Preparation" by Ms. Shweta Joshi, Soft skill Trainer	31-03-2021
25.	Attire for Interviews, Dr. Shivani Desai, Asst. Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune	01/04/2021
26.	An online pre-placement training session on "Orientation on Job profile as Junior Scientific and Medical Writer and interview process" of Springer by Mr. Punit Ganatra, Human Resource, Springer Nature	06/04/2021
27.	Opportunities For Pharma Students in Management Education, Prof. Nitpal Singh, Deputy Director, Pharmaceutical Management, MITCON Institute of Management, Pune	08/05/2021
28.	Higher studies, Dr. S. P. Gandhi, Assistant Professor and Academic Incharge, DPU Pharmacy, Pune	19/05/2021
29.	Mock Interview for Job Opportunities in Regulatory Affairs, GSK by Mr. Sachin Gundecha, Industry Expert & Placement Cell	27 & 28 /05/ 2021
30.	Higher education and Career Opportunities Abroad, Mr. Chetan Jain, Managing Director, Study Smart Overseas Education, Pune	29/05/2021
31.	An online "Pre-placement guidance & interactive session for Regulatory Affairs, GSK" by Mr. Nateque Syed, Regulatory Affairs Department, GSK, was organized by Placement Cell, DPU Pharmacy	01/06/2021
32.	Importance of Virtual Internships and Trainings, Dr. Shivani Desai, Asst. Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune	04/06/2021
33.	An online "Pre-placement guidance & interactive session for D.Pharm and B.Pharm aspirants for Production, Gennova Biopharmaceuticals & Business Executive, Neuvocare Pharmaceutical" by Placement Cell.	05/06/2021
34.	An online "Pre-placement Talk: guidance & interactive session for	09/06/2021



	campus drive of Macleods for various positions, for D.Pharm, B.Pharm, M.Pharm, Bsc & Msc" by Mr. Amit Kanabar, Head - Completed Centre of Excellence, Sarigam Mr. Amritsingh, Head - Macleods Centre of Excellence, Baddi, Mr. Krishna, Head - Macleods Centre of Excellence, Sikkim. (Skill Development Centre) Macleods Pharmaceuticals Ltd.,	
35.	Introductory Session on LinkedIn, Dr. Shivani Desai, Asst. Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune	28/06/2021
36.	Management Studies after, B. Pharm, Ms. Swati Shinde, Assistant Professor, Dr. D. Y. Patil Institute of Management and Research, Pimpri, Pune	14/07/2021
37.	Sophisticated Instrument Training	04/08/2021 to 07/08/2021
38.	Counseling session: Career in Medical Coding	07/09/2021
39.	Role of Healthcare professional in adverse drug reaction and pharmacovigilance, Dr. Ajit Singh, Co-Founder and CEO, Climbed Research Solutions, Haryana	17/09/2021
40.	Pre Placement requirements for Career in Pharmacovigilance, Mr. Vishal Chaudhari, Head of operation, Clini India (National Level Workshop on Pharmacovigilance- 11 am to 12 noon)	18/09/2021
41.	Pharmacovigilance: Interview preparation and Career Scope, Mr. Pritam Bhangale, Asst. Manager (Safety OPS), Tata Consultancy Services (National Level Workshop on Pharmacovigilance- 12 noon to 1pm)	18/09/2021
42.	Prerequisites for placement and career in Pharmacovigilance, Mr. Nitin Patil, Team Lead- Domain Training, Cognizant Technology Solutions (National Level Workshop on Pharmacovigilance- 2 pm to 3 pm)	18/09/2021
43.	Interview preparation for freshers, Mrs. Shweta Joshi, Assistant Training Manager, Heaxwere Technologies (National Level Workshop on Pharmacovigilance- 3 pm to 4:30 pm)	18/09/2021
44.	Pharmacovigilance -The Need of the Hour, Dr. Sarita Mulkalwar, Professor, Dept. of Pharmacology, Dr. D. Y. Patil Vidyapeeth, Pune	20/09/2021
45.	Guidance Session on career survey to B. Pharm, M.Pharm and D. Pharm. Students	24/09/2021
46.	Industrial visit of students at Haffkine Bio-Pharmaceutical Corporation Limited, Pune	24 & 25/09/2021
47.	Training IELTS Study Smart	11-10-2021 4 weeks
48.	Strategy for GPAT and NIPER preparation, Pharmaelite, Pune	21/10/2021



49.	Guidance session on essential aspects of RA in India, which may include: Basic Fundamentals of Regulatory Affairs. Introduction to Quality Standards for Regulatory Compliance by Sanda Sai Kiran (Online workshop on Regulatory Affairs conducted in collaboration with GSK - 9:05-9: 50 am)	17/11/2021
50.	Overview - Regulatory Publishing by Ramyakrishna Sunkara (Online workshop on Regulatory Affairs conducted in collaboration with GSK - 9:55-10: 45 am)	17/11/2021
51.	Registration Data Management /Regulatory Information management / Records management / Archival by Shweta Kulkarni (Online workshop on Regulatory Affairs conducted in collaboration with GSK - 11:00- 11:45 am)	17/11/2021
52.	Drug Labelling Overview by Kalp Jamalta (Online workshop on Regulatory Affairs conducted in collaboration with GSK - 11: 45 am - 12: 45 pm)	17/11/2021
53.	EU variation by Chandra chukka (Online workshop on Regulatory Affairs conducted in collaboration with GSK - 1:45- 2:30 pm)	17/11/2021
54.	Interpersonal skills, Ms. Hazel Francis, Corporate Training Consultant, Life Skill & Language Coach, Pune	28/12/2021
55.	Aptitude Training Workshop Mr. Pavan Nemiya, Aptitude Trainer, Friends Union for Energising Lives (FUEL), Pune	20/12/2021 to 22/12/2021



Chitlange
Dr. S. S. Chitlange
(Principal)

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Offer letters**

Ref No: 16938570

09-Jul-2021

Shweta Kishor Nikumbh,
Bachelor of Pharmacy,
Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research.

Dear Shweta,

With reference to the discussions that we had with you, we are pleased to offer you the role of **Trainee - Junior Data Analyst** in **Cognizant Technology Services India Private Limited ("Cognizant")**.

You are entitled to an Annual Total Compensation (ATC) of **Rs.249,996/-** The other details about your compensation are presented in **Annexure A**.

We are glad to also offer you one time Joining Bonus. Please refer **Annexure C** for further details.

Your appointment will be governed by the terms and conditions of employment presented in Employment Agreement (**Annexure B**). You will also be governed by the rules, regulations and practices in vogue and those that may change from time to time. Your compensation is highly confidential and if the need arises, you may discuss it only with your Project Manager.

Please note:

- This appointment is subject to satisfactory professional reference checks.
- This offer from Cognizant is valid for 3 months only from the date of offer, any extension in said validity shall be at the discretion of the company and shall be communicated to you in writing.
- Prior to commencing employment with Cognizant you must provide Cognizant with evidence of your right to work in India and other such documents as Cognizant may request.

We look forward to you joining us. Should you have any further questions or clarifications, please reach us on TAGCDBOTeam@cognizant.com.

Yours sincerely,
For **Cognizant Technology Solutions India Private Ltd.**



Suresh Bethavandu
Global Head - Talent Acquisition

I have read the offer, understood and accept the above mentioned terms and conditions.

Signature:

Date:

Annexure A

Name: Shweta Kishor Nikumbh

Designation: Trainee -Junior Data Analyst

Sl. No.	Description	Monthly	Annual
1	Basic	7,300	87,600
2	HRA	2,920	35,040
3	Conveyance Allowance*	800	9,600
4	Medical Allowance*	1,250	15,000
5	Company's contribution of PF #	1,800	21,600
6	Advance Statutory Bonus***	2,000	24,000
7	Special Allowance*	4,227	50,724
8	Company's Contribution for ESI @ 3.25% of Monthly Gross Minus Statutory exclusions	536	6,432
	Annual Gross Compensation (AGC)		249,996
	Annual Total Compensation (ATC)		249,996
	Company's contribution towards benefits (Medical, Accident and Life Insurance)		19,500
	Annual Total Remuneration		269,496

As an associate you are also entitled to the following additional benefits:

- Floating Medical Insurance Coverage
- Round the Clock Group personal accident Insurance coverage
- Group Term Life Insurance Coverage
- Employees' compensation insurance benefit as per the Employees' Compensation Act, 2010
- Gratuity, on separation after 4 years and 240 calendar days of continuous service, payable as per Payment of Gratuity Act.

Leave & Vacation:

- From the Date of your Joining, you will be entitled with the below mentioned leaves as per your eligibility in line with the statutory requirements. You shall be entitled to avail the leaves only with prior approval from your Manager.

SI No	Category of Leave	No. of leave days
1	Earned Leave	18
2	Sick Leave	12
3	Casual Leave	6

- From the Date of Joining, Women associates will be entitled to Maternity leave based on the eligibility as laid down in The Maternity Benefit (Amendment) Act, 2017
- In addition to the above, as per Cognizant policy you are also eligible to avail Child Adoption leave and Paternity leave by adhering to the conditions as laid down in the India Leave Policy.

Provident Fund Wages:

For the purpose of computing contribution to Provident Fund, Pension Fund & EDLI Scheme, “Monthly Gross Salary as per Annexure A of this letter excluding “Advance Statutory Bonus” & “House Rent Allowance” will be considered. This does not include payments made through “Special Payout”.

Determination of PF Wages for the purpose of contribution: PF contribution shall be payable on the earned PF wages or PF wages as per this letter, whichever is lesser.

Employee State Insurance

ESI Eligible Wages Eligibility to ESI shall be decided by deducting the Advanced Statutory Bonus, Employer PF & ESI contribution from the monthly Gross Compensation (AGC/12) as per Annexure A of this letter

Earned ESI Wages: Monthly ESI contribution will be computed on total remuneration paid to an Associate in a particular month which includes any recurring (or) adhoc special payouts during the month

ESI Contribution shall be continued till end of the contribution period (Apr to Sep & Oct to Mar), if the Associate contributes even for one month in the said contribution period

* **Flexible Benefit Plan:** Your Compensation has been structured to ensure that you are adequately empowered to apportion components of your salary in a manner that suits you the best. This plan will enable you to

1. Choose from a bouquet of allowance or benefits
2. Redefine your salary structure within prescribed guidelines
3. Optimize your earnings.

***** Advance Statutory Bonus** is in line with the provisions of Payment of Bonus Act, 1965.

Note:

- Any statutory revision of Provident Fund/ESI Contribution or any other similar statutory benefits will result in a change in the Net take home salary and the Annual Gross Compensation will remain the same.
- Cognizant has made this offer in good faith after expending significant time and resources in the hiring process. We hope you will join us, but appreciate your right to pursue another path. Your formal commitment to joining us forms the basis of further planning and client communication at Cognizant. If you renege on the commitment and decide not to join us after signing the offer letter, Cognizant reserves the right to not consider you for future career opportunities in the company. We look forward to welcoming you to Cognizant.

Annexure C

It was a great pleasure interacting with you over the last few weeks.

With reference to our discussion and subsequent offer, we wish to inform you of an additional joining bonus of **Rs.50,000/-** and this will be paid in 1 Installment (after completion of 3 months of your joining in Cognizant).

Kindly note the points below:

- The joining bonus will be subject to statutory and income tax deductions as applicable.
- The joining bonus will be recovered in case you leave us within one year of joining.

I have read the offer, understood and accept the above mentioned terms and conditions.

Signature:

Date:

**Springer Nature Technology and
Publishing Solutions**

Tower 8 & 9, Magarpatta City SEZ
Hadapsar, Pune - 411013
Maharashtra, India

T +91 20 7100 7000

F +91 20 7100 7100

www.springernature.com

May 06, 2021

Tamanna Vajirsaheb Tamboli

Mahadev Mandir Javal, At PO Upale,
Dumala TA- Barshi, Upale (Dumala),
Solapur, Maharashtra - 413401

Dear Tamanna,

We are pleased to offer you employment with “**Springer Nature Technology and Publishing Solutions Private Limited**” upon the terms and conditions set forth in this Contract of Employment (“Agreement”) as “**Junior Scientific and Medical Writer**” in the **Publishing Solutions**. As mutually discussed, we confirm your joining on or before ‘**May 10, 2021**’. The details of your employment are mentioned in this Agreement.

1. Salary

- 1.1. Remuneration: You shall receive an annual compensation package, details of which are provided in Annexure A of this Agreement, which shall be subject to such deductions for tax at source, as applicable.
- 1.2. The Company shall be entitled, at any time during your employment, or in any event of termination, howsoever arising, to deduct from your remuneration any monies due from you to the Company, including but not limited to salary, loans or advances and any excess holiday pay.
- 1.3. Please note that the details of the compensation payable to you are strictly confidential between you and the Company and you shall not divulge these particulars to any other person.

2. Probation

- 2.1. You shall initially be on probation for a period of 90 days from the actual date of joining the Company. The probation can be extended further as per the probation confirmation process of the Company.

3. Place of Work

- 3.1. Initially you will be based out of our office at Tower 8 & 9, Magarpatta City SEZ, Hadapsar, Pune 411 013, Maharashtra, India. However, you may at any time be transferred to any another department, unit or location of the Company in India or any branch/subsidiary overseas as may be considered necessary by the Company.
- 3.2. The Company may also depute you to any work or assign your services to any affiliates, associate company, branch, office, joint venture, subsidiary or other companies, concerns, organizations, or firms with whom the Company may make any such arrangement or agreement. You may also be required on a temporary basis to work at any office based in India or overseas.

4. Background Check

The Company may conduct a background check verifying your education, previous employment, permanent address, court records check and any other information as may be deemed reasonably necessary by the Company. Should such background check prove unsatisfactory or reveal that the facts have been misrepresented to seek employment, the Company shall deem it to be a misconduct on your part and the Company shall have the right to terminate your employment with immediate effect (without any notice period).

5. Intellectual Property

- 5.1. If at any time during your employment, you solely or jointly, create, conceive, develop, originate, make or design or reduce to practice (whether in a written document, photograph, electronic or digital format or any other medium) or cause to be created, conceived, developed, etc. any Intellectual Property arising from your duties for, or employment with, the Company or Group of Springer Nature companies, it shall be owned exclusively by and shall vest in the Company. Without prejudice to the generality of this Clause 5, you will also be required to assign to the Company any URL or trade mark that is registered by you personally or on your behalf during your employment and that arises from your duties for, or employment with, the Company or any Group of Springer Nature companies. For the avoidance of doubt, any Intellectual Property created, originated, made or designed by you that does not arise from your duties, such as a private website created in your own time which is not competing or related to or similar to the business or activities of the Company, shall be owned by you and not the Company.
- 5.2. In this clause "Intellectual Property" means copyright, patents, goodwill, database rights, rights in confidential information, inventions, original works of authorship, developments, concepts, source codes, computing programs, know-how and any research work, improvements or trade secrets, and all other intellectual or industrial property rights in any part of the world, including the right to sue for past infringements, patents, rights in designs, trademarks and service marks (whether registered or unregistered) including any applications for any of the foregoing inventions, discoveries or improvements.
- 5.3. You will at the request and expense of the Company sign all documents and do such things as may be necessary or desirable to vest or assign, or confirm vesting or assignment of, any such Intellectual Property (referred to in this clause) to the Company, to obtain protection in the Company's name for that Intellectual Property and in order to assign and convey to the Company, its successors, assigns, and nominees, the sole and exclusive rights, title and interest in and to such Intellectual Property.
- 5.4. Attorney-in-Fact. If the Company is unable for any reason, to secure your signature for the purpose of applying for or pursuing any application for any intellectual property registration covering the Intellectual Property assigned to the Company, then you hereby irrevocably designate and appoint the Company and its authorized officers and agents as your agent and attorney-in-fact, to act for and on your behalf to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of such registrations with the same legal force and effect as if executed by yourself.
- 5.5. To the fullest extent permitted by law, you irrevocably and absolutely waive and relinquish in favor of the Company all rights, title and interest (including any moral rights) in any part of the world that you may have in any of the said Intellectual Property belonging to the Company pursuant to this clause and you hereby acknowledge and covenant that you do not and shall not have any rights, title or interest therein in future.
- 5.6. The provisions of this clause will continue in force after the termination of this Agreement in respect of all Intellectual Property created, originated, made or designed by you during the course of your employment.
- 5.7. You will not use, integrate or disclose any third party data or materials that are not validly licensed by the Company unless previously authorized by your manager. You will not infringe or assist others in infringing the Intellectual Property Rights of any third party made available to you by virtue of your employment at any time. You will indemnify the Company (its subsidiaries or its affiliates, their shareholders, directors, officers and employees), promptly upon demand and without any protest or demur, against any losses, liabilities, litigation and expenses suffered or likely to be suffered by the Company resulting from or in any way arising out of any infringement by you of the Intellectual Property Rights of any third party.

6. Non-Compete and Non-Solicitation

- 6.1. You will not during the term of this Agreement and for a period of 2 (two) years following the date of termination of your employment, do or permit any of the following without the prior written consent of the Company.
- 6.1.1. Be concerned with, engaged or interested in, collaborate, or advise or own any business directly or indirectly, which is in competition with any business carried on by the Company, including without limitation companies engaged in similar activities as those of the Company as were performed or developed at any time during your tenure;
- 6.1.2. Solicit customers or any person who is or has been a customer of the Company for the purpose of offering to that person goods or services similar to or competing with those of the Company;
- 6.1.3. Cause or permit any person directly or indirectly under your control to do any of the acts or things specified above;
- 6.1.4. Solicit any employee(s) of the Company, which includes persons employed by the Company after termination of your employment with the Company, for the purpose of offering to that person an employment of any interest in any other company, institution, organization or any business whether owned by you or not.
- 6.2. You recognize and agree that, by reason of your knowledge and access to trade secrets and confidential information of the Company, the covenants contained herein are required to protect the trade secrets, confidential information and goodwill of the Company, its subsidiaries and affiliates and any breach or attempted breach of any of the above conditions will result in immediate and irreparable injury for which the Company will not have an adequate remedy at law, and shall entitle the Company to a decree of specific performance of these restrictions and to a temporary and permanent injunctive relief enjoining the breach thereof to enforce the above mentioned restrictions, and to seek any and all other remedies to which the Company may be entitled at law, including, without limitation, monetary damages, without posting bond or furnishing security of any kind.
- 6.3. You agree that the Company shall not be obligated to make any payments or provide any benefits pursuant to this Agreement if you, during the period in which such payments are being made or benefits provided, engage in any of the activities constituting a breach of this Agreement including specifically this Clause 6 or otherwise act or conduct yourself to the detriment of the Company, its subsidiaries or affiliates. The foregoing provisions of this sub-clause are in addition to and not by way of limitation of any other rights and remedies available to the Company.
- 6.4. You represent and warrant that (i) You have read and understand the covenants contained herein and their contemplated operation and believe, that they are fair and reasonable; (ii) You recognize and agree that the restriction on your activities contained herein are required for reasonable protection of the Company. In the event that such restriction shall be found to be void, but would be valid if some part thereof was deleted or the scope, period or area of application were reduced, the above restrictions shall apply with the deletion of such words or such reduction of scope, period or area of application as may be required to make the restrictions contained in this Clause valid and effective. This Clause shall survive termination or expiry of this Agreement.

7. Termination of Employment

- 7.1. Before confirmation of your employment, during the probation period:
- a) The Company may terminate your services by giving Thirty Days' notice (or salary in lieu thereof) without assigning any reasons thereof, at the sole discretion of the Company.
- b) You may terminate your employment with the Company by giving Thirty Days written notice.
- 7.2. After confirmation of your employment:
- a) Your appointment with the Company is liable to be terminated by the Company, without cause, by giving you Ninety Days written notice or salary in lieu thereof, or

- b) You may terminate your employment with the Company by giving to the Company Ninety Days written notice or by payment of salary in lieu thereof. Provided that the option of payment of salary in lieu of notice period shall be at the sole and absolute discretion of the Company.

You agree and undertake to work with the Company during the aforesaid term of notice. You will be allowed to adjust the annual leaves as per your eligibility against the notice period which will be at the sole and absolute discretion of the Company. You further agree that in case you fail to give the requisite notice, or do not perform your services during your notice period and are absent from duty during any part of the notice period without approval of the Company, the Company shall be entitled to make proportionate deductions from your salary or any other payments due to you for such absence.

You further agree and understand that giving of prior written notice and completion of the notice period is a material obligation of yours, inter alia to ensure smooth handover of your assignments/tasks to other personnel of the Company and to avoid any undue interruption of business/activities of the Company. Accordingly, if you terminate your employment in violation of this Clause 7.2 (b), you shall, in such a case, be immediately obligated to pay to the Company, an amount equal to your gross salary for the unserved notice period, as damages, in one lump sum payment. Provided that no provision of this Clause is intended to curtail, reduce or otherwise affect adversely any other rights that the Company may have against you in respect of unlawful termination by you or any other breach(s) under this Agreement or any other policies of or agreement with the Company.

- 7.3. If at any time, in the opinion of the Company, which shall be final and binding, you are found guilty of dishonesty, disobedience, disorderly behavior, negligence, indiscipline, commission/omission which may be prejudicial to the interest of the organization, absence from duty without permission, or of any conduct unbecoming of the status or the post you hold in the Company, or of any other conduct considered by the Company as detrimental to its interests or in violation of one or more terms and conditions of your employment, or any breach of this Agreement or policies of the Company, the Company shall be entitled to forthwith terminate your employment, without any notice, and salary in lieu of notice or compensation.

8. Retirement

Retirement age for all employees shall be 60 years.

9. Other Terms and Conditions

- 9.1. Your position with the Company calls for whole time employment and you will devote yourself exclusively to the business of the Company. You shall not take up any other work for remuneration or otherwise or work on advisory capacity or be interested directly or indirectly (except as shareholder or debenture holder) in any other trade or business or profession or any gainful or commercial activity, whether part-time or full time, directly or indirectly, during the employment with the Company, without prior written permission from the Company.
- 9.2. As an employee of the Company, you hereby agree to abide and be legally bound by all the rules and regulations, non-disclosure agreement, employee hand book, terms of service, policies, circulars, addendums issued and as amended from time-to-time by the Company, which shall form part of this Agreement and any breach of the same shall be considered as a breach of this Agreement. Copies of certain policies (including the terms of service) have also been uploaded and made available to the employees on the Company's intranet, and it is, your responsibility to review the policies including any amendments made therein and you are encouraged to check the policies and terms of service frequently.

10. Return of Company Property/Documents


Upon cessation/termination of your employment with the Company, you shall promptly (and in any event during the applicable notice period, if any) return to the Company (and will not keep in your possession, recreate or deliver to anyone else) all devices, records, data, equipment, other documents or property, belonging to the Company or any other confidential information or Intellectual Property, and handover all your assignments/tasks in the manner and in the form as required by the Company. Failure to comply with this provision shall constitute a material breach of this Agreement by yourself, and the Company shall be entitled to make such deductions from the salary or any other amounts due to you as it deems appropriate.

11. General

- 11.1. **Binding Agreement; Successors.** This Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns and any person, firm, corporation or other entity which succeeds to all or substantially all of the business, assets or property of the Company. This Agreement and all your rights hereunder shall inure to the benefit of and be enforceable by your personal representatives, executors, administrators, heirs, devisees and legatees. If you should die while any amounts are due and payable to you hereunder, all such amounts, unless otherwise provided herein, shall be paid to your designated/nominated beneficiary or, if there be no such designated beneficiary, to the legal representatives of your estate.
- 11.2. **Amendments.** Any amendments or modification of this Agreement shall not be binding unless made in writing and signed by the Company through an authorized officer and yourself.
- 11.3. **Notices.** All notices, requests, demands or other communication required or permitted to be given under this Agreement and the provisions contained herein shall be written in English and shall be sent by nationally recognized courier or by registered post (with acknowledgment due), postage prepaid to the parties at their address mentioned above. Notice may also be sent by the Company to the employee vide email at the email address provided by the employee. All notices so given shall be deemed given when sent, provided that any notice of termination or resignation hereof shall be deemed given only when received.
- 11.4. Failure or delay by the Company to enforce any provision of this Agreement shall not be deemed a waiver of future enforcement of that or any other provision.

12. Governing Law; Jurisdiction

This Agreement and any other documents relating to this Agreement shall be governed and construed in accordance with the laws of India. The jurisdiction concerning any dispute arising out of your employment or breach or termination thereof will be with the courts in Pune only.

DocuSigned by:

007881898EF6441...
06 May 2021

Hiral Dholakia
Associate Director - Human Resources
Springer Nature Technology and Publishing Solutions Private Limited

Acceptance

I, **Tamanna Vajirsaheb Tamboli**, have read and understood the above terms and conditions governing my services and employment with Springer Nature Technology and Publishing Solutions Private Limited and the same are acceptable to me.

Place: Solapur

Signature: 
Date: 06 May 2021

Enclosed:

Annexure A – Salary Break up
Annexure B – Terms of Service
Annexure C – Other Benefit
Annexure D – Non-Disclosure Agreement

Annexure A


SALARY BREAK UP

Name Tamanna Vajirsaheb Tamboli
Job Title Junior Scientific and Medical Writer
Vertical Publishing Solutions

Sr. No.	Particulars	Annual	Monthly	Remarks
1	Basic Salary	182,400	15,200	
2	House Rent Allowance	72,960	6,080	
3	Leave Travel Allowance	-	-	
4	Food Coupons	-	-	
5	Personal Allowance	47,002	3,917	
A	Base Pay/ Gross	302,362	25,197	
B	Others			
	Statutory Bonus	27,000		- This is an indicative amount. - The actual payout will be as per the provisions of the Payment of Bonus Act, 1965 as may be revised from time to time by government authorities.
	ESIC Employer's Contribution	-	-	
	Total of B	27,000	-	
	Total (A+B)	329,362	25,197	
C	Retirals			
	Gratuity	8,750	729	
	Employer's Contribution to PF	21,888	1,824	
	Total of C	30,638	2,553	
	A+B+C	360,000	27,750	

Note:

1. All amounts in Indian Rupees

DocuSigned by:

 007881898EF6441...
 06 May 2021

Hiral Dholakia

Associate Director - Human Resources
 Springer Nature Technology and Publishing Solutions Private Limited

Place: Pune, Maharashtra.

Acceptance

I, Tamanna Vajirsaheb Tamboli, have read and understood the above Compensation package related to my services and employment with Springer Nature Technology and Publishing Solutions Private Limited and the same is acceptable to me.

Place: Solapur

Signature: 
 Date: 06 May 2021

Annexure B**Terms of Service (Revision C)****Work Schedule**

The Company provides for a 9 hour working day, Monday through Friday, the timings of which will be decided based on business requirements. Half Day working will mean 4 hours of work per shift.

The Company expects all employees to assume responsibility for their attendance and promptness. If you are unable to report to work or if you arrive later than your scheduled start time, you are expected to speak directly with your manager to inform him or her. If your manager is not available, then you are expected to follow the process as otherwise stipulated by your manager. Absence from work for three (3) consecutive days without notifying your manager, or any other person designated by the manager or your Human Resources representative, will be considered absconding/ having abandoned your services, and the Company shall be entitled to take such actions as provided for in your employment contract and the separation policy read with other terms and conditions of your employment.

Workplace Attire

You are expected to maintain an overall professional appearance that is appropriate for your position and clients/colleagues you support. Your appearance should be neat and clean at all times. Specific dress standards may apply for certain events or functions, such as tradeshows. Any employee who comes to work dressed in a manner that is considered inappropriate may be sent home to change and may be disciplined, up to warning letter. Examples of inappropriate attire include:

Shirts with slogans, profanity, inappropriate symbols, or insignias or language/images that are vulgar, obscene, threatening, intimidating, or a violation of the Company's policies against discrimination, harassment, Tank tops, sports jerseys, muscle shirts, halter tops, crop tops, dirty, ripped, torn, or frayed shirts or pants, Gym attire etc.

Employee ID Card (ID Card)

The ID Card should be worn in office premises at all times. It should be visible to all. Loss of ID Card must be immediately reported to Admin department. A duplicate ID Card will be issued at a cost. If ID Card is forgotten, support staff will make relevant entry in the register. Please swipe your ID Card every time you enter or exit the office. The ID Card must be returned to the Admin department on cessation of employment.

Provident Fund

Contribution to Provident Fund is made as per Employees Provident Fund and Miscellaneous Provisions Act, 1952 as amended from time to time.

Statutory Bonus

Statutory Bonus, if applicable, is paid as per 'Payment of Bonus Act (1965)' as amended from time to time.

Gratuity

In the event of termination of your employment with the Company, after the 5th year of continuous service with the Company, you will be entitled to receive a gratuity payment from the Company in accordance with the Payment of Gratuity Act, 1972 as amended from time to time.

ESIC

Only eligible employees are covered under Employees State Insurance Act 1948 as amended from time to time. It is a multidimensional social security system tailored to provide socio-economic protection to employee population and their dependents covered under the scheme besides full medical care for self and dependents. This is health statutory benefit by law for the employees.

Code of Conduct

To ensure orderly operations and to provide the best possible work environment, the Company expects all employees to conduct themselves in a manner that will protect the interests and safety of all employees at the workplace. Any violation of the Code of Conduct on social media by the employee will be treated as violation of the Code of Conduct at the workplace if it is in connection with Springer Nature's business or its employees or anyone connected with Springer Nature. It is not possible to list all the forms of conduct that are considered unacceptable at the workplace. However, the following are some examples of conduct that may result in disciplinary action, up to and including immediate termination of employment. The list is not comprehensive and is not intended to, nor shall it be deemed to alter the "at-will" nature of the employment relationship.

- Unauthorized disclosure of confidential information or breach of the confidentiality/secretary provisions.
- Theft or inappropriate removal or possession of Company property.
- Working under the influence of alcohol or illegal drugs.
- Possession, distribution, sale or use of alcohol or illegal drugs in the office premises.
- Negligence or improper conduct leading to damage of Company or customer-owned property.
- Trading any securities without the express written permission of the Managing Director.
- Insubordination or other disrespectful conduct.
- Smoking in prohibited areas.
- Being late for work.
- Absence from work without prior notice in writing or without sufficient cause.
- Going on or abetting a strike in contravention of any law.
- Illegal duplication of computer software or reproducing copyrighted information without written permission from authorized personnel of the Company.
- Unauthorized use or abuse of telephones, Internet, mail system or other Company equipment or data channels.
- Unauthorized use of Mobile phones in the facility.
- Possession of dangerous or hazardous materials.
- Unwelcome, harassing or offensive conduct as judged by any reasonable observer.
- Continued discharge of work functions which do not meet the standards reasonably expected by the Company or continued poor performance.
- Persistent violation of the dress code.
- Violation of personnel policies, including sexual harassment, working at another company without permission etc.
- Commission or attempt to commit any cyber-crime.
- Criminal conviction.
- Anything that impairs the Company's reputation.

- Borrowing/Accepting/Giving Gifts or Favors in contravention of Company policies.

The employees shall at all times, comply with all applicable laws in relation to anti-corruption, both domestically and otherwise. The employees acknowledge that breach of this policy would be a material breach incapable of remedy. Therefore, in addition to the other rights, the Company may terminate the employment agreement immediately and without notice if it reasonably considers the employee is in breach of this anti-bribery policy.

Employees are also governed by Springer Nature's Global Code of Conduct Policy and must read and abide by the policy available on the Company's intranet.

- Prevention of Sexual Harassment

The Company has a ZERO Tolerance policy towards any kind of sexual harassment, irrespective of the gender of the aggrieved employee. In accordance with the Govt. of India policy, any complaint of sexual harassment of women will be investigated by the ICC of the Company under the POSH Policy. Similarly, any complaint of sexual harassment of any other gender will be investigated under the Work Conduct Policy of the Company.

Company Policies & Procedures

Employees should refer and adhere to the applicable Company policies and processes uploaded on the Company intranet.

Disclaimer

The Company reserves the right to modify this document, amend or terminate any policies, procedures, or employee benefit programs whether or not described in this document at any time, or to require and/or increase contributions toward these programs. All policies contained herein were adopted by the Company and supersede previous policies. We periodically review policies in part or as a whole and introduce new policies, to ensure that they continue to reflect current thinking in the field of Human Resource Management and are consistent with trends and legislative requirements. The updated and/or new policies shall be made available to the employees on the Company's intranet, and it is, the responsibility of the employee to review such new policies and existing policies for any such changes and the employee is encouraged to check the policies frequently.

Annexure C**1. Insurance:**


- 1.1. **Group Health Insurance Policy:** You shall be insured under Group Health Insurance Policy. The insurance covers your immediate family (Self + Spouse + 2 Children) for a maximum sum of INR 3,00,000 (Three Lakhs Only).
- 1.2. **Group Personal Accident Policy:** You shall be insured under Group Personal Accident Policy for a sum of three times of your annual gross salary (round off to INR 25000) from the actual date of joining.
- 1.3. **Group Term Life Policy:** You shall be insured under Group Term Life Policy for a sum of three times of your annual gross salary (round off to INR 25000) from the actual date of joining.

2. Leave:

- 2.1. **Annual (privilege or earned) Leave:** 18 days of Annual Leave during the calendar year i.e., January to December.
- 2.2. **Casual Leave:** 08 days of Casual Leave during the calendar year i.e., January to December.
- 2.3. **Public Holidays:** 10 days of Public Holidays as per list released by the company.

3. **Relocation Expenses:** Relocation expenses not exceeding INR 50000 for the purpose of movement of household expenses and one way air ticket (Economy Class) reimbursement for your family (includes self + spouse + two dependent children or self + two dependent parents) would be borne by the Company as a one-time expense and will be reimbursed to you along with your salary after completion of three months. The amount is conditional to a minimum continuous service period of 18 months, from your actual start date with the Company. The relocation expense has to be pre-approved by the Company and will be paid out on actuals upon submission of receipts. Should you and the Company decide to part ways 'voluntarily or involuntarily' prior to 18 months; this amount will be recovered from your full & final settlement.

DocuSigned by:



007881898EF6441...

06 May 2021

Hiral Dholakia

Associate Director - Human Resources

Springer Nature Technology and Publishing Solutions Private Limited

Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Higher studies admission proof**



NIPER JOINT ENTRANCE EXAMINATION - 2021

CONDUCTED BY NIPER, HYDERABAD




AHMEDABAD | GUWAHATI | HAJIPUR | HYDERABAD | KOLKATA | RAEBARELI | SAS NAGAR |

NIPER Joint Entrance Examination 2021 for Admission in MS (Pharm)/M.Tech (Pharm) / M.Tech/ M.Pharm/MBA (Pharm)/Ph.D.

Provisional Seat Allotment Letter

Dear Candidate,


Congratulations! This is to inform that you have been allotted seat in **NIPER SAS Nagar** as per your AI Rank obtained in NIPER JEE-2021 for Admission in MS (Pharm)/M.Tech (Pharm) / M.Tech/ M.Pharm/MBA (Pharm)/Ph.D.

Application No	11810032015	
Secret Code	F9D438AA451	
HallTicet No	2111112224	
Candidate's Name	PATIL UMESH BHANUDAS	
All India Rank	147	
Category Allotted	EWS	
Course Allotted	M.S.(Pharm.) Medicinal Chemistry	
Institute Allotted	NIPER SAS Nagar	Candidate's Signature

Undertaking:-

- I undertake that my admission is provisional subject to the submission and verification of valid document mentioned overleaf.
- I declare, that in case I am unable to submit the above mentioned certificates / documents for physical verification/validation within the time limit that is notified by the NIPER-JEE 2021, I shall not claim any equity on account of admission against the allotted seat. I also state that I am well aware of the fact that my admission is completely subject to the physical verification/validation of my original certificates otherwise my admission is liable to be cancelled & all the fees deposited by me shall be forfeited.
- I agree, that if any falsified records are detected at any stage of admission or during the course of study & even after I pass out my course, my admission to the course shall liable to be cancelled or the degree awarded by the NIPER shall be taken back. Further, I will be debarred from attending any course at NIPER for the next 05 (Five) years and in addition, a criminal case under relevant section(s) of law in force may be initiated against me.
- I undertake that I shall abide by the Rules & Regulations of the NIPER. I also hereby undertake that I shall accept the decision of the NIPER- JEE Committee-2021 as final if the seat allotted to me is taken back or if my admission is cancelled due to submission of incorrect certificates/non-submission of certificates within the duration of time allotted as above, to furnish the same.
- I further declare that I have submitted the result of qualifying degree exam / will submit the result of qualifying degree/certificate as stated above, before the commencement of Final Semester examination at respective NIPER, otherwise my provisional admission shall be cancelled and full fees deposited by me shall be forfeited and no claim will be made by me.
- I have a knowledge that as per the norms of NIPER a fellowship is given to all successful candidates who are granted admission in different courses (except MBA (Pharm)) through NIPER JEE 2021 counseling. I understand if till the date I do not submit my result of qualifying examination and other required documents mentioned overleaf as per the NIPER JEE 2021 norms, I would not be eligible for fellowship and further till that date-I will not claim any fellowship from the NIPER.

(Signature of the Candidate)



COMMON ADMISSION TEST 2020 (CAT 2020)

INDIAN INSTITUTES OF MANAGEMENT



CAT 2020 SCORE CARD

Name of the Candidate : SONAWANE SHIVRAJ DIPAK

Candidate's Contact Details :

Sukhwani Campus, Carnation flat no-06 Vallabh Nagar Pimpri, Pune-18

Town/City : Pimpri Chinchwad

District : Pune

State : Maharashtra

Email : shivrajsonawane.24@gmail.com



Test Day Photo




Uploaded Photo

CAT Registration Number	20104435	PWD Status	No
Gender	Male	Category	General
Date of Birth	24/Sep/1999	Date of Test	29th Nov 2020

Section		Section		Section		Total	
Verbal Ability & Reading Comprehension		Data Interpretation & Logical Reasoning		Quantitative Ability			
Scaled Score	Percentile	Scaled Score	Percentile	Scaled Score	Percentile	Overall Scaled Score	Overall Percentile
18.5	72.17	-2.14	12.25	0.55	25.92	16.92	36.36

Instructions:

- Only those candidates who have taken the Common Admission Test (CAT 2020) are entitled to receive the score card. Keep a print-out of this score card for your information pertaining to CAT 2020. You will not receive the score card by email or by post.
- The Overall Scaled Score is the sum of the scaled scores of the candidate in the three sections.
- Percentile refers to the percentage of candidates who receive a scaled score less than or equal to the scaled score obtained by the candidate.
- IIMs and Non-IIM member institutions independently decide how to use CAT 2020 scores in line with their own selection process. The scores are to be used only for selecting the candidates to their respective Post Graduate/Fellow Programme(s) in Management.
- Detection of instances of incorrect information and process violation by a candidate at any stage will lead to disqualification of the candidate. CAT scores of such candidates who are disqualified will become null and void. Such disqualified candidates will not be allowed to appear for CAT in future. If such instances go undetected during the current selection process but are detected in subsequent years, such disqualification and the associated penalties will take place with retrospective effect.
- All queries regarding post-CAT 2020 selection process must be directed to the respective IIMs. CAT Centre will not answer post-CAT queries.
- CAT 2020 score is valid only until 31st December 2021 and is subject to the candidate meeting the minimum eligibility marks in the qualifying examination. The score card will be available on www.iimcat.ac.in till 31st December 2021 to download.
- Webmail support cat2020@iimidr.ac.in & cathelpdesk@iimcat.co.in will be available till 31st March 2021.



Dr. D.Y. Patil Unitech Society's
Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri,
Pune-18

- **Careerthone: A Skill Enhancement Training Programme**
- **Award Details**

NATIONAL EDUCATIONAL EXCELLENCE AWARDS & CONFERENCE 2020

2020
EDUCATIONAL EXCELLENCE
AWARDS & CONFERENCE
www.eduawards.in

Certificate of Appreciation

DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL
SCIENCES AND RESEARCH, INDIA

PRESENTED TO

DR. D. Y. PATIL INSTITUTE OF PHARMACEUTICAL
SCIENCES AND RESEARCH

CATEGORY

INNOVATIVE TEACHING APPROACH,
PLACEMENTS & QUALITY EDUCATION

ON FRIDAY , 27TH OF NOVEMBER , 2020 AT
THE TAJ WEST END , BENGALURU, KARNATAKA

PRESENTED BY

BEGINUP RESEARCH INTELLIGENCE PRIVATE LIMITED



Dr Anand Gopal Naik
Managing Director
Beginup Research Intelligence Pvt. Ltd.

PRESENTED BY



www.beginup.com

BEGINUP RESEARCH INTELLIGENCE PRIVATE LIMITED

www.eduawards.in